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Abstract 
Exogenous Pyruvate Is Required for Cell Adaptation to Chronic Hypoxia 
Chengqian Yin  
Advisor: Nianli Sang, Ph.D. 
Hypoxia is a common feature in solid tumors due to the imbalance between the 
poor development of vascularization and rapid proliferation of tumor cells. Tumor 
hypoxia is associated with poor clinical prognoses and is correlated with tumor 
progression and metastasis. The Pasteur and Warburg effects have been well described in 
which endogenous glycolytic pyruvate is converted to lactate to maintain the intracellular 
NAD+ levels. However, a role of exogenous pyruvate in cell adaptation to hypoxia has 
not been fully investigated. My thesis research focuses on exploring how exogenous 
pyruvate facilitates cellular adaptation to chronic hypoxia. 
In the thesis, I demonstrate that exogenous pyruvate is required for cellular 
adaption to chronic hypoxia through supporting ATP generation and NAD+ recycling, 
sustaining ER stress response and regulating autophagy and apoptosis. Specifically, by 
using both hypoxic and ρ0 cells with defective mitochondrial electron transfer chain, I 
show that exogenous pyruvate is required to sustain the proliferation of cancer and non-
cancer cells that cannot utilize oxygen. Particularly, I show that absence of pyruvate led 
to glycolysis inhibition, ATP depletion and decreased NAD+ levels in ρ0 cells; and 
exogenous pyruvate increases lactate yield, elevates NAD+/NADH ratio and ATP 
production. Knockdown of lactate dehydrogenase A (LDHA) significantly inhibits the 
rescuing effects of exogenous pyruvate. On the other hand, pyruvate derived metabolites,
xii                
including acetyl-CoA, α-ketoglutarate, succinate and alanine do not rescue ρ0 cell 
proliferation. Knockdown of pyruvate carboxylase (PC), pyruvate dehydrogenase subunit 
(PDHA1) and citrate synthase (CS) do not impair exogenous pyruvate to rescue ρ0 cells. 
Importantly, I show that exogenous pyruvate enhances ATP levels and promotes the 
proliferation of hypoxic cells, and that well-oxygenated cells release pyruvate, providing 
a potential in vivo source of pyruvate. These findings support a novel pyruvate cycle 
model in which oxygenated cells release pyruvate for hypoxic cells as an oxygen 
surrogate (Chapter 2).  
Autophagy and apoptosis are critical in cell fate determination. I show that 
hypoxia causes autophagy as demonstrated by LC3 conversion and autophagosome 
formation, and exogenous pyruvate further enhances autophagy. I also demonstrate that 
exogenous pyruvate protects tumor cells from chronic hypoxia-induced apoptosis 
(Chapter 3). 
ER stress response plays an important role in cell adaptation to the micro-
environmental stresses including hypoxia and nutrient insufficiency. I show that although 
activated by acute hypoxia, the three ER stress response branches, the eIF2α-ATF4 
pathway, the ATF6 pathway and the XBP1 pathway are inhibited by chronic hypoxia. 
This inhibition is blocked in the presence of exogenous pyruvate (Chapter 4).  
I also show that the master regulator and downstream target of ER stress response, 
GRP78, plays a critical role in hypoxic cell adaptation. GRP78 knockdown with 
CRISPR/cas9 gene editing technique impairs the exogenous pyruvate-mediated rescue of 
hypoxic tumor cells.  Thus, my findings delineate that exogenous pyruvate activates ER 
stress response and promotes cell survival under hypoxia (Chapter 5). 
xiii                
In summary, my data show that exogenous pyruvate prevents NAD+ exhausting 
and ATP depletion, and maintains ER stress responses under chronic hypoxia, which in 
turn promotes cellular adaption to hypoxia by coordinately regulating autophagy and 
apoptosis. 
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Chapter 1: Background 
 
Cardiovascular diseases and cancer are the top two leading causes of death in 
United States. One of every three deaths in the United States in 2014 were caused by 
heart disease, stroke and other cardiovascular diseases, according to American Heart 
Association’s 2016 Heart Disease and Stroke Statistics Update (Mozaffarian et al., 2016). 
The Cancer Facts & Figures 2016 from American Cancer Society reveals that cancer is 
estimated to cause 595,690 deaths in Unites States in 2016, which is nearly 25% of total 
deaths. How to improve prevention and treatment of cardiovascular diseases and cancer 
is an urgent and important mission for biomedical research. 
Although the causes and symptoms of cardiovascular diseases and cancer are 
diverse and complicated, ischemia accompanied by hypoxia is always one of the most 
critical contributing factors to the pathological processes and poor prognosis (Giordano, 
2005a; Hockel and Vaupel, 2001; Wilson and Hay, 2011). Hypoxia refers to the 
condition in which oxygen concentration is low and not adequate to support normal 
physiological behaviors and functions. As molecular oxygen is transported within blood 
flow, ischemia often results in insufficient oxygen supply. For cardiovascular diseases, 
buildup of fatty plaques in blood vessels limits the blood flow to the organs and tissues, 
particularly heart and brain, and the consequent lack of nutrients and oxygen causes 
inevitable damages (Julian, 2007). In solid tumors, due to the rapid consumption of 
oxygen in mitochondria respiration and other oxidation activities and poorly developed 
vascularization, oxygen availability is often limited in certain regions of solid tumor 
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tissues (Liao and Johnson, 2007; Yin et al., 2012b). Therefore, hypoxia is an important 
characteristic property of cardiovascular diseases and cancer.  
Cells usually utilize oxygen as an electron acceptor in oxidative phosphorylation 
to generate ATP and recycle NAD+ in mitochondria (Vaupel et al., 1989). When oxygen 
concentration is below a critical threshold, cells turn to cytosolic glycolysis and lactate 
fermentation as the alternative way for energy production and redox status balance, 
which is well defined as Pasteur effect (Krebs, 1972). In tumor cells, this metabolism 
transformation exists even in the presence of ample oxygen, which is now well known as 
Warburg effect (Vander Heiden et al., 2009; Warburg et al., 1927). The transformation of 
cancer metabolism involves the participation of multiple signaling pathways related to 
metabolism regulation, including hypoxia-inducible factors (HIF) pathway, AMP-
activated protein kinase (AMPK) pathway, mechanistic target of rapamycin (mTOR) 
pathway, ER stress response pathways and some other oncogenic signaling pathways 
(Archer, 2011; Cairns et al., 2011a; Semenza, 2009b). As a key connection between 
glycolysis and lactate fermentation, pyruvate plays a key role in the metabolic adaptation 
in hypoxia and tumor cells. To study the role of pyruvate in cellular adaption to hypoxia 
and its potential effect on different signaling pathways may shed some light on a novel 
therapeutic target in treatment for cancer and cardiovascular diseases. 
This chapter attempts to summarize the current knowledge of physiological roles 
of hypoxia in normal tissues and tumors and the consequent adaption to hypoxia through 
cellular metabolism and various signaling pathways. I will introduce how hypoxia is 
associated with solid tumors and ischemic tissues, and how tumor cells adapt themselves 
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through metabolism transformation. Some important signaling pathways including HIF 
pathway, AMPK pathway, mTOR pathway, and ER stress response pathways will be 
introduced respectively. Particularly, some novel findings about functions of ER stress 
response regulator GRP78 will be presented. 
 
1) Physiological and clinical significance of hypoxia 
Tissue hypoxia results from the insufficient supply of molecular oxygen (O2) that 
impairs cellular biological functions (Hockel and Vaupel, 2001; Korner, 1959). The 
causes of tissue hypoxia are diverse, such as 1) compromised tissue perfusion capability 
due to blood clotting or vascular disorganization, 2) low oxygen partial pressure in 
arterial blood resulting from high attitude or pulmonary dysfunctions; 3) reduced ability 
of blood to transport oxygen as a result of disruptive hemoglobin formation or carbon 
monoxide poisoning; 4) increased diffusion distance to microvessels; 5) inhibited ability 
to utilize oxygen because of intoxication or defective electron transfer chain (ETC) in 
mitochondria (Sutherland, 1998). In solid tumor tissues, due to the spatial disorganization 
of tumor vascular networks, intercapillary distances are often far beyond the diffusion 
ability of oxygen in solid tumor tissues, which is up to 200 μm based on the local oxygen 
tension in blood plasma (Leach and Treacher, 1998). In addition to the limited diffusion 
of oxygen, the blood flow in tumor vascularization system is occasionally unstable, 
leading to fluctuating disturbed perfusion hypoxia (Dewhirst et al., 2008). Even though 
oxygen utilization in tumor cells has been inhibited because of oncogenic and metabolic 
reprogramming (Cairns et al., 2011a), a critical level of oxygen consumption still remains 
in tumor cells to maintain fundamental needs for cell survival and functions (Chen et al., 
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2009), which further decreases the oxygen availability to the areas distant from the tumor 
capillaries (Fig. 1-1). Hypoxia is also strongly associated with cardiovascular diseases 
(Carmeliet and Jain, 2000). As the plaque builds up in the arteries, the resistance of blood 
flow greatly increases, limiting the transport of blood to the tissues and resulting in 
hypoxia (Lerman and Zeiher, 2005) (Fig. 1-2). The mammalian heart and brain are 
obligate aerobic organs with high demand for oxygen supply. The heart consumes 
approximately 8–15 mL O2/min/100 g tissue at a resting pulse rate, and can increase to 
more than 70 mL O2/min/100 g myocardial tissue during vigorous exercise (Brown and 
Giaccia, 1998; Giordano, 2005b). Thus, a constant supply of oxygen is vital to sustain 
heart function and viability. Brain is one of the most sensitive tissues to oxygen 
availability. Lack of oxygen supply for as acute as 5 minutes may cause inexorable 
damage to brain cells (Doppenberg et al., 1998). Therefore, hypoxia is a primary 
pathophysiological feature in both tumor and normal tissues. 
An appropriate detection method is required to assess the extent of hypoxia in 
tumors and tissues. During the past decades, many methods and techniques to directly or 
indirectly evaluate oxygenation status have been developed and improved. In the early 
days for hypoxia study, to measure plasma arterial lactate level and pH change was 
applied to indirectly assess tissue hypoxia as it is easy and a good indicator of metabolic 
status of hypoxic tissues (Chapman, 1991; Mueller-Klieser et al., 1991; Walenta et al., 
2000). With the development of microsensor techniques, invasive oxygen electrode for 
direct measurement of tissue oxygen tension has been widely used (Griffiths and 
Robinson, 1999; Hockel et al., 1991; Stone et al., 1993). Increasingly, clinical evaluation 
of tissue hypoxia has been shifting to the monitoring of endogenous hypoxic markers 
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including the transcriptional targets of hypoxia-inducible factors (HIFs) such as carbonic 
anhydrase 9 (CA9) and exogenous immunohistochemical 2-nitroimidazole probes such as 
pimonidazole and nitroimidazole-theophylline (Jubb et al., 2010; Parliament et al., 1992; 
Sevick et al., 1991; Tatum et al., 2006). Quantitative assessment of hypoxia in tumors 
and normal tissues remains to be completed, but the spatial distribution and duration of 
hypoxia and the effects on genetic and metabolic reprogramming have been established 
and contribute to deeply understanding the complicated consequences of hypoxia in 
tumors and normal tissues. 
In cellular metabolism, the major function of molecular oxygen is to serve as the 
electron acceptor in mitochondria oxidative phosphorylation for adenosine triphosphate 
(ATP) production and NAD+ recycling (Chernyak and Kozlov, 1986; Cross et al., 1984; 
Rottenberg, 1990). When oxygen supply is reduced to a critical level not adequate to 
support oxidative phosphorylation, a significant consequence caused by hypoxia is the 
imbalance of cellular NAD+/NADH homeostasis (Riva et al., 1998). NADH and NAD+ 
are a pair of electron transfer intermediates for energy generation and other metabolic 
pathways (Canto et al., 2015; Ying, 2008a). NAD+ is necessary to accept electrons in a 
variety of metabolic pathways such as glycolysis in the cytoplasm and the TCA cycle and 
oxidative phosphorylation in the mitochondria (Houtkooper et al., 2010). In cytosolic 
glycolysis, after conversion of glucose to two molecules of glyceraldehyde-3-phosphate 
(G3P), two molecules of NAD+ are required to accept electrons from G3P to guarantee 
the continuation of glycolysis, which is mediated by the enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Yang et al., 2007). The generated NADH may be 
transported into mitochondria matrix via either the malate-aspartate shuttle or the 
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glycerol-3-phosphate shuttle (Billington et al., 2008; Chuang et al., 2005). In 
mitochondria, electrons from pyruvate and TCA cycle intermediates are transferred to 
NAD+ with participation of pyruvate dehydrogenase complex (PDC), isocitrate 
dehydrogenase (IDH), α-ketoglutarate dehydrogenase (OGDC), and malate 
dehydrogenase (MDH) (Hsu and Sabatini, 2008). NADH from glycolysis and TCA cycle 
then transfer electrons to Complex I (NADH:ubiquinone oxidoreductase) of the ETC. In 
parallel, succinate dehydrogenase (SDH) mediates the electron transfer from succinate to 
FAD+. The subsequent flow of electrons along ubiquinone (Coenzyme Q10), complex III 
(coenzyme Q-cytochrome c oxidoreductase), cytochrome c, and Complex IV 
(cytochrome c oxidase) to the final acceptor molecular oxygen lead to pumping of proton 
from the mitochondrial matrix to the intermembrane space, resulting in the proton 
gradient. The proton gradient then provides the chemiosmotic force to convert ADP to 
ATP via FoF1-ATP synthase with oxidative phosphorylation. Under conditions of 
hypoxia oxygen cannot be used as the final electron acceptor, and thus NAD+ is 
exhausted and ATP generation is inhibited (Magni et al., 1999; Sazanov, 2015; Sazanov 
et al., 2013). Besides the important role in energy generation, NAD+ also serves as the 
substrate of sirtuins, poly(ADP-ribose) polymerases (PARP) and cyclic ADP-ribose 
synthases, essential enzymes for cellular signaling pathways and DNA damage repair 
(Aksoy et al., 2006a; Aksoy et al., 2006b; D'Amours et al., 1999; Fliegert et al., 2007; 
Maeng et al., 2004; Papadimitriou et al., 2015; Sauve et al., 2006; Ying et al., 2003; Ying, 
2008b). Therefore, hypoxia-induced NAD+/NADH imbalance leads to energy restriction 
and perturbed signaling pathways.  As the “molecular unit of currency”, ATP transfers 
energy to support nearly all the fundamental cellular functions and activities, including 
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biosynthesis of macromolecules such as proteins, DNA and RNA, cell structure 
construction and locomotion, and signal transduction processes (Knowles, 1980; 
Maruyama, 1991; Tornroth-Horsefield and Neutze, 2008). Thus, hypoxia-induced energy 
insufficiency further globally compromises cellular behaviors and functions. 
Another potential consequence of hypoxia is the generation of reactive oxygen 
species (ROS) (Cross et al., 1987; Gorlach et al., 2015). Although the exact relationship 
between oxygen tension and ROS production remains controversial, it has been 
established that hypoxic environment is a critical factor contributing to ROS formation 
(Clanton, 2007; Tafani et al., 2016; Zuo et al., 2013). Most intracellular ROS are derived 
from reduction of oxygen by gaining a single electron from a NADPH oxidase (NOX) or 
electron leak in mitochondria ETC, which generates superoxide (O2∙-) (Bedard and 
Krause, 2007; Lambeth, 2004; Lee and Yang, 2012). The superoxide molecules can be 
converted to the non-radical ROS hydrogen peroxide (H2O2) by the enzyme superoxide 
dismutases (SOD) (Rhee, 2006; Szatrowski and Nathan, 1991). Through Fenton 
chemistry with Fe2+, hydrogen peroxide is converted to the extremely reactive HO∙-, 
which may cause serious cellular damages (Schallreuter et al., 2012). Alternatively, 
hydrogen peroxide can be reduced to water (H2O) by the enzymes glutathione 
peroxidases (GPXs), peroxiredoxins (PRXs), or catalase, which is the important 
scavenger reaction of excessive ROS (Handy and Loscalzo, 2012). Hydrogen peroxide 
may also participate into oxidation of cysteine residues on proteins, which plays a crucial 
role in cell signaling (Sena and Chandel, 2012). Superoxide is also suggested to be a 
signaling ROS molecule (Buetler et al., 2004).  
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It has been demonstrated by numerous studies that ROS plays a critical role in 
signaling transduction for cell survival, proliferation, mobility and metabolism. ROS has 
been shown to oxidize the active site cysteine of PTEN, resulting in inactivation of PTEN 
and the perpetual action of the phosphoinositide 3-kinase (PI3K) pathway (Downes et al., 
2004; Luo et al., 2013). The PI3K pathway is a central growth factor response pathway 
responsible to increase proliferation, promote survival, and increase cellular mobility 
(Vanhaesebroeck et al., 2012). ROS is also required for the stabilization of catalytic 
subunit of hypoxia-inducible factors (HIFs), which is the master transcription regulator 
mediating the adaptation to hypoxia (Qutub and Popel, 2008).  Through HIFs, ROS 
increases glucose uptake and glycolytic flux, and diverts cell metabolism from 
mitochondria respiration to cytosolic glycolysis (Zhao et al., 2014). Besides HIFs, ROS 
can also modify metabolism through activating NRF2, which increases synthesis of 
anabolic enzymes and supports tumor growth by inducing production of NADPH and 
purine biosynthesis (Frohlich et al., 2008; Shah et al., 2007). However, excessive 
accumulation of ROS results in oxidative stress, which exerts significantly detrimental 
damages including DNA and protein damage and impaired DNA repair (Finkel, 2003). 
Furthermore, oxidative stress induces destruction of plasma membrane structure and 
permeability through lipid peroxidation (Aitken et al., 1989) . 
Whether hypoxia increases or decreases ROS production is still a matter of debate, 
and there is still no general consensus regarding the exact relationship between different 
severity of hypoxia and ROS formation and the precise mechanism underlying the 
potential relationship. A group of studies have provided evidence that ROS formation is 
induced by conditions of acute hypoxia or ischemia (Clanton, 2007; Hernansanz-Agustin 
9 
 
et al., 2014a; Liu et al., 2008; Zuo et al., 2013). It is suggested that the formation of ROS 
is due to the effects of hypoxia on the electron transfer chain (ETC) in mitochondria, the 
major source of ROS formation. Particularly, Complex III was reported to be necessary 
for hypoxia-induced ROS production (Guzy et al., 2005). Moreover, the use of ETC 
inhibitors results in the inhibition of ROS accumulation under hypoxia (Wang et al., 
2015). However, the amounts of ROS measured under conditions of hypoxia and 
ischemia are considerably low and appear to be transient. The detection of ROS 
formation under hypoxia and ischemia also intend to be affected by the coexisting 
conditions including acidosis, nutrient or energy depletion, sheer stress, nitric oxide (NO) 
accumulation or depletion (Giaccia et al., 2004). The precise relationship between 
hypoxia and ROS formation remains to be fully investigated. 
Hypoxia also has clinical significance in tumor treatment and prognosis as it 
causes the tumors resistance to standard therapies including ionizing radiation and 
anticancer drugs (Wilson and Hay, 2011). The radiation therapy kills tumor cells through 
inducing DNA damage, particularly DNA double strand break, which requires the 
presence of oxygen for oxidation (Wouters and Brown, 1997). Therefore, radiation 
therapy is less effective for hypoxic tumors. The resistance to chemotherapy comes from 
several reasons (Bhangal et al., 2000; Holohan et al., 2013). First, hypoxic regions are 
usually distant from blood vessels, and not sufficiently exposed to anticancer drugs. 
Second, some anticancer drugs resemble radiotherapy and need to the presence of oxygen 
to increase cytotoxicity to DNA. Third, hypoxia selects tumor cells with malignant 
phenotypes and expression of genes involved in drug resistance such as p-glycoproteins. 
Therefore, hypoxia plays a crucial negative role in radio- and chemotherapy for tumors. 
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However, on the other hand, hypoxia is a unique feature in tumors as a specific 
therapeutic target (Kizaka-Kondoh et al., 2003). The particular condition of low oxygen 
supply contributes to development of four strategies specific for hypoxic cells: prodrugs 
activated by hypoxia; hypoxia-selective gene therapy; targeting HIFs; and recombinant 
obligate anaerobic bacteria (Liu et al., 2014; Powis and Kirkpatrick, 2004; Yeh and Kim, 
2015). 
 
2) Metabolic alteration of cancer cells 
It has become a thorough understanding that compared to the non-transformed 
cells, tumor cells undergo a dramatic change in the cellular metabolism. Warburg effect 
and glutamine addiction are two of the most noticeable metabolic alterations.  
Warburg effect is defined as the increased glucose uptake and enhanced activity 
of glycolysis and lactate fermentation even in the presence of sufficient oxygen (Heiden 
et al., 2009). Distinguishable from Pasteur effect, which is mainly induced by hypoxia-
inducible factors (HIFs) and focuses on anaerobic glycolysis, Warburg effect is 
characterized as aerobic glycolysis (Chen et al., 2007; Lu et al., 2002b) (Fig. 1-3). This 
raised a paradox that still has not been completely resolved: why do tumor cells rely on 
the wasteful form of metabolism instead of the highly efficient mitochondria respiration 
(Kim and Dang, 2006)? Several reasons have been proposed for the advantages of 
aerobic glycolysis in tumor cell growth. First, tumor cells are immersed in the 
microenvironment with fluctuating oxygen tensions due to defective oxygen supply. 
Aerobic glycolysis grants tumor cells the advantage to avoid oxygen dependence for 
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oxidative phosphorylation and survive in conditions of various oxygen tensions. Second, 
enhanced glucose uptake guarantees the substrate supply for pentose phosphate pathway 
(PPP) which produces sufficient amount of NADPH for anti-oxidant defense for hostile 
microenvironment and reductive macromolecules synthesis. Third, upregulated lactate 
fermentation increases acidosis in the surrounding environment and contributes to 
metastasis and invasion of tumor cells. Last but most importantly, Warburg effect 
satisfies the primary demand of tumor cells for biomass production with the intermediates 
of glycolytic pathway. Glucose-6-phosphate from phosphorylation of glucose by 
hexokinase II (HK II) supports production of glycogen and ribose-5-phosphate. 
Dihydroxyacetone phosphate (DHAP) can also be utilized for triglycerides and 
phospholipid synthesis, which are key building blocks for cell membrane structure. 
Particularly, the end product of glycolysis, pyruvate, plays a vital role in tumor cell 
metabolism (Semenza, 2008). One of the major metabolic role of pyruvate is to serve as 
the electron acceptor in the conversion to lactate via the lactate dehydrogenase (LDH), 
whereby NADH is converted to NAD+. Besides that, pyruvate is a key metabolite to 
support biosynthesis of diverse metabolites. With the pyruvate dehydrogenase complex 
(PDC), pyruvate is dehydrogenated to acetyl CoA, which is the major substrate to enter 
the TCA cycle and synthesis of fatty acids, cholesterol, and isoprenoids. Pyruvate is also 
a starting point for gluconeogenesis through carboxylation to oxaloacetate (OAA) by 
pyruvate carboxylase (PC). Through transamination pyruvate is converted to alanine to 
support nitrogen metabolism (Feron, 2009; Kroemer and Pouyssegur, 2008; Yin et al., 
2012b)(Fig. 1-4). Therefore, Warburg effect provides tumor cells the advantage to grow 
and survive in the stressful tumor microenvironment. 
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Another important metabolism alteration in tumor cells is that tumor cells need 
increased glutamine supply, making glutamine switch from a nonessential amino acid 
(NEAA) to an essential amino acid (EAA) (Wise and Thompson, 2010; DeBerardinis et 
al., 2008b). After entering tumor cells through glutamine transporters, glutamine is 
converted to ammonia and glutamate through glutaminolysis. Glutamate in turn can be 
catabolized to α-ketoglutarate (α-KG) through either transamination or oxidative 
deamination (Chen and Russo, 2012; Zhao et al., 2013). Therefore, unlike glucose with 
only carbon skeleton, glutamine provides both carbon and nitrogen for anabolism (Coloff 
et al., 2016; Meng et al., 2010). It is knowns that glutamine-derived nitrogen is the 
primary source for nitrogenous compounds, including nucleic acids, glucosamines, and 
NEAAs, and glutamine-derived carbon can be used in anaplerosis to support the 
truncated TCA cycle in tumor cell mitochondria, which in turn compensate for the 
enhanced cytosolic glycolysis and inhibited mitochondria TCA cycle (Yang et al., 2014). 
The mechanism underlying alteration of cancer metabolism has been has been 
extensively investigated. Now, it is widely acknowledged that the crosstalk of multiple 
transcription regulators, metabolism regulators and oncogenic signaling pathways is the 
major driving force of metabolism alteration in tumor cells, including hypoxic-inducible 
factors, AMP-activated protein kinase (AMPK), mechanistic target of rapamycin 
(mTOR), and ER stress response, which will be respectively introduced in details as 
below. 
 
3) Hypoxia-inducible factors  
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The family of hypoxia-inducible factors (HIFs) is the master transcriptional 
regulator mediating adaptive responses to the hypoxic microenvironment in tumors 
(Dang and Semenza, 1999; Hellwig-Burgel et al., 2005; Semenza, 2003b). HIFs activate 
the transcription of genes involved in critical aspects of cancer biology, including glucose 
metabolism, cell survival and proliferation, angiogenesis, and therapy resistance (Greer et 
al., 2012; Semenza, 1999; Volm and Koomagi, 2000). Hypoxia-inducible factors consist 
of HIF-1, HIF-2 and HIF-3. They are all heterodimers composed of a specific catalytic 
subunit (HIF-1α, HIF-2α and HIF-3α) and a shared β subunit (HIF-β) which is also 
known as aryl hydrocarbon receptor nuclear translocator (ARNT) (Lee et al., 2004; 
Semenza, 2012). HIF-1 and HIF-2 are the two major transcription regulators of hypoxia-
related target genes and HIF-3α is proposed to function primarily as a dominant negative 
regulator of HIF-1α and HIF-2α (Acker et al., 2001). Even though HIF-1 and HIF-2 have 
overlapping downstream targets, they have distinctive specificities regarding to 
physiological inducers and target gene activation (Loboda et al., 2010). HIF-1 is 
ubiquitously expressed in all tissues while HIF-2 is differentially expressed in tissues 
with preference in endothelial cells (Ratcliffe, 2007). Structurally, HIF-1 and HIF-2 are 
both basic helix-loop-helix (bHLH) transcription factor belonging to PER-ARNT-SIM 
(PAS) family. HIF-1α, HIF-2α and HIF-β have similar structures, containing a bHLH 
domain to bind DNA, a PAS domain for heterodimeration and transactivation domain for 
transcriptional activity (Talks et al., 2000; Wang et al., 1995).  
HIF-1α is regulated through two well-known oxygen-dependent pathways. First, 
in the presence of molecular oxygen, HIF-1α is hydroxylated by prolyl hydroxylase-
domain protein 1-3 (PHD 1-3) at two prolyl residues P402 and P564 with α-ketoglutarate 
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and iron ion as cofactors. The hydroxylated HIF-1α is then recognized by the VHL 
tumor-suppressor protein. VHL is the recognition component of an E3 ubiquitin-protein 
ligase which targets HIF-1α for degradation by 26S proteasome (Huang et al., 1998; 
Kondo et al., 2002; Salceda and Caro, 1997; Tanimoto et al., 2000; Wang et al., 1995; 
Wenger and Gassmann, 1997). The second mechanism involves the hydroxylation of 
HIF-1α transactivation domain by factor inhibiting HIF-1 (FIH). FIH mediates the 
hydroxylation of asparagine 803, which blocks the interaction of HIF-1α with co-
activators p300 and CBP. Oxygen insufficiency inhibits hydroxylation of HIF-1α by 
PHD and FIH, thus induces accumulation and transactivation of HIF-1α (Kallio et al., 
1997; Lando et al., 2002; Sang et al., 2003). The oxygen-dependent hydroxylation of 
HIF-1α has also been proposed as the biochemical basis of oxygen-sensing pathway.  
HIF-1 plays a critical role in cellular adaption to hypoxia through global 
transcriptional and metabolic reprogramming (Pennacchietti et al., 2003). HIF1 
dramatically increases uptake and utilization of glucose to reduce the dependence on 
oxygen and facilitate cell survival and proliferation through upregulating expression of 
glucose transporters including glucose transporter 1 (GLUT1) and enzymes involved in 
glycolysis including hexokinase 2 (HK2), phosphofructokinase 2 (PFK2), 
glyceraldehyde-3-phosphate dehydrogenase (GADPH) and pyruvate kinase 2 (PK2) 
(Lum et al., 2007b; Robey et al., 2005; Semenza, 2009a).  The stimulated expression of 
lactate dehydrogenase (LDH) and pyruvate dehydrogenase kinase (PDK) further 
contributes to transformation of mitochondria oxidative phosphorylation to cytosolic 
lactate fermentation (Firth et al., 1995; Kim et al., 2006a). HIF-1 also upregulates the 
expression of carbonic anhydrase 9 (CA9) to facilitate neutralization of excessive 
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generation of intracellular lactate, granting tumor cells the benefits to survive in the harsh 
microenvironment to compete with surrounding normal cells (Chiche et al., 2009). 
Besides metabolism transformation, HIF-1 also promotes angiogenesis and erythropoiesis 
through upregulating downstream targets including vascular endothelial growth factor 
(VEGF) and erythropoietin (EPO) to facilitate oxygen transport to hypoxic regions 
(Forsythe et al., 1996; Haase, 2013; Lin et al., 2004). Moreover, HIF-1 is reported to 
contribute to invasion, metastasis and cell survival through diverse downstream target 
genes (Fukuda et al., 2003; Manalo et al., 2005; Ryan et al., 1998; Zagzag et al., 2000). In 
a word, HIF-1 plays a key role in adaptive responses to hypoxic microenvironment in 
tumors and is a promising therapeutic target for cancer treatment and prognosis. 
 
4) AMPK signaling pathway  
AMP-activated protein kinase (AMPK) is a central regulator of cellular 
metabolism and energy production (Mihaylova and Shaw, 2011b). AMPK is an obligate 
heterotrimer consisting of catalytic α subunit and two regulatory subunits (β and γ subunit) 
(Hardie et al., 2011; Xiao et al., 2011). AMPK has been demonstrated to be activated by 
upstream regulators under different specific context (Thornton et al., 2011; Xiao et al., 
2011). In eukaryotic cells, the concentrations of ATP and ADP are much higher than that 
of AMP; a slight decrease of ATP level leads to a remarkable change of AMP levels. 
Therefore, change of AMP concentration is a more sensitive indicator of energy status. 
When the cellular ATP level is low, AMP concentration increases, which directly binds 
the regulatory γ subunit of AMPK, thus inducing a conformational change that promotes 
the phosphorylation and activation of AMPK at Thr 172 (Oakhill et al., 2011; Salt et al., 
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1998; Viollet and Andreelli, 2011). Increased AMP levels also protect phosphorylated 
AMPK from dephosphorylation (Wang et al., 2003). It has been demonstrated by several 
groups that the tumor suppressor LKB1 (also named STK11) mediates the 
phosphorylation of AMPK at Thr 172 (Shackelford and Shaw, 2009; Shaw et al., 2004; 
Woods et al., 2003). In addition, AMPK may be phosphorylated on Thr 172 by 
CAMKK2 kinase in response to calcium flux (Hawley et al., 2005; Woods et al., 2005). 
Moreover, the mitogen-activated protein kinase kinase kinase (MAPKKK) family 
member TAK1 also contributes to the phosphorylation of AMPK on Thr 172 (Cargnello 
and Roux, 2011; Mihaylova and Shaw, 2011a).  
The AMPK pathway is a master sensor and regulator of cellular and organismal 
energy status (Fig. 1-5). In conditions of hypoxia and nutrient insufficiency, AMPK is 
activated by low energy level and thus inhibits cell growth to reserve energy. The most 
extensively studied downstream effector of AMPK is the mechanistic target of rapamycin 
(mTOR) pathway (Kim et al., 2011; Xu et al., 2012). Activated AMPK inhibits mTOR 
pathway through indirectly phosphorylating the tumor suppressor and negative regulator 
of mTOR TSC2 and directly phosphorylating mTOR complex subunit Raptor (Gwinn et 
al., 2008a; Inoki et al., 2012; Kudchodkar et al., 2007). As the mTOR pathway is 
responsible for macromolecule synthesis and cell growth (which will be introduced in 
details in next section), activated AMPK-mediated inhibition of mTOR inhibits 
anabolism and cell growth (Gleason et al., 2007; Green et al., 2011). Another important 
mechanism to reserve energy is the induction of autophagy (Alers et al., 2012b). It was 
reported that AMPK can trigger autophagy to recycle damaged macromolecules and 
reserve energy through directly phosphorylating the autophagy-initiating regulator ULK1 
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and indirectly inhibits mTOR activity, which has the suppressive effect on ULK1 (Alers 
et al., 2012a; Shang and Wang, 2011). Interestingly, AMPK stimulates mitophagy in the 
ULK-dependent manner to trigger the destruction of defective mitochondria and 
stimulates de novo mitochondria biogenesis through increasing the transcriptional 
coactivator PGC-1α (Lee et al., 2006). Thus, AMPK controls the replacement of existing 
defective mitochondria with newly-generated functional mitochondria to facilitate ATP 
generation (Egan et al., 2011). AMPK activation can also cause a G1 phase cell cycle 
arrest and prevent the entry into S phase where a large amount of ATP is required 
through targeting tumor suppressor p53 and the cyclin-dependent kinase (CDK) inhibitor 
p27 (Imamura et al., 2001; Jones et al., 2005; Short et al., 2008).  
Besides controlling cell growth and survival, another important role of AMPK is 
to regulate metabolism though short-term direct phosphorylation of metabolic enzymes 
and long-term transcriptional regulation. The well-investigated substrates of AMPK are 
acetyl-CoA carboxylase (ACC1 and ACC2) and 3-hydrxy-3-methyl-glutaryl-CoA 
reductase (HMG-CoA reductase), which are rate-limiting enzymes in fatty acid and 
cholesterol synthesis (Chen et al., 2000; Foretz et al., 2005; Kemp et al., 1999; Stephens 
et al., 2002; Zhang et al., 2009). In transcriptional reprogramming, one important 
substrate of AMPK is the lipogenic transcription factor SREBP1 (McFadden and Corl, 
2009; Porstmann et al., 2008). SREBP1 induces a wide spectrum of genes involved in 
fatty acid and lipid production, including ACC1 and FASN (Eberle et al., 2004). The 
phosphorylation of SREBP1 by AMPK at a conserved serine near the cleavage site of 
SREBP1 suppresses its activation (Li et al., 2011). Also, it is suggested that AMPK 
phosphorylates the glucose-sensitive transcription factor ChREBP, which controls 
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expression of genes in glucose metabolism and lipid synthesis overlapping with SREBP1 
(Ferre et al., 2003; Uyeda and Repa, 2006). AMPK is also reported to phosphorylate a 
number of transcription regulator and coactivators, such the acetyltransferase p300 and 
histone deacetylases including HDACs and SIRT1 (Huang et al., 2013; Lim et al., 2012; 
Lin et al., 2012; Ruderman et al., 2010). Interestingly, one class IIa HDAC member 
HDAC5 is phosphorylated by AMPK, resulting in 14-3-3 binding and cytoplasmic 
sequestration. As previously reported by our lab, HDAC5 is required for HIF-1 
accumulation and activation through protein chaperones HSP70 and HSP90 (Chen et al., 
2015b). As AMPK participates in regulation and localization of HDAC5, AMPK 
contributes to the regulation of HIF-1 activity, which plays a critical role in glucose 
utilization and cellular adaptation to hypoxic microenvironment.  
 
5) mTOR signaling pathways 
 
The mechanistic target of rapamycin (mTOR) signaling pathway plays a key role 
in nutrient sensing and regulation of cell survival and growth (Laplante and Sabatini, 
2012). mTOR is an atypical serine/threonine protein kinase belonging to the 
phosphoinositide 3-kinase (PI3K)-related kinase family and forms two distinct complexes 
named mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) with different 
regulatory protein components (Sauer et al., 2013; Yang et al., 2013).  mTORC1 mainly 
responds to change in amino acid availability, oxygen tension and energy status, growth 
factors and diverse stresses to regulate anabolic and catabolic processes and drive cell 
cycle progression. mTORC2 is less characterized and mainly sensitive to growth factors 
to regulate cell metabolism and survival (Costa-Mattioli and Monteggia, 2013).  
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The major upstream regulator of mTORC1 is the heterodimer consisting of 
tuberous sclerosis 1 and 2 (TSC1, also known as hamartin and TSC2, also known as 
tuberin), which functions as GTPase-activating protein (GAP) for the Ras homolog 
enriched in brain (Rheb) GTPase (Byles et al., 2013; Curatolo and Moavero, 2012). 
mTORC1 is activated when interacting with the GTP-bound form of Rheb, and TSC1/2 
negatively regulates mTORC1 activity by converting Rheb into its inactive GDP-bound 
state (Inoki et al., 2003a; Inoki et al., 2003b). TSC1/2 transmits signals of many growth 
factors to regulate mTORC1, such as insulin and insulin-like growth factor1 (IGF1) 
(Miyazaki et al., 2010; Patursky-Polischuk et al., 2009; Vander Haar et al., 2007). 
Diverse signaling pathways have also been reported to regulate mTORC1 activity 
through TSC1/2, including protein kinase B (PKB/Akt), extracellular-signal-regulated 
kinase 1/2 (ERK1/2), ribosome S6 kinase (RSK1), proinflammatory cytokines such as 
tumor necrosis factor-α (TNFα), IκB kinase β (IKKβ) and glycogen synthase kinase 3β 
(GSK3-β) (Feng, 2010; Inoki et al., 2002; Ma et al., 2006; Pearce et al., 2011; Zhang et 
al., 2006). Similarly, the stressful conditions also regulate mTORC1 through TSC1/2. 
Under conditions of hypoxia and low ATP status, which commonly exist in tumor 
microenvironment, AMPK is activated and phosphorylates TSC1/2 to inhibit mTORC1 
activity (Brugarolas et al., 2004; Gwinn et al., 2008b).  It was reported that AMPK also 
directly inhibits mTORC1 through phosphorylating the complex component raptor, 
leading to 14-3-3 binding and allosteric inhibition (Alayev and Holz, 2013). 
The mTOR signaling pathway plays a crucial role in regulation of protein 
synthesis (Fig. 1-6). Two best-defined downstream targets phosphorylated by mTORC1 
are the translation regulators eukaryotic translation initiation factor 4E (eIF4E)-binding 
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protein 1 (4E-BP1) and p70 S6 kinase 1 (p70S6K1) (Magnuson et al., 2012; She et al., 
2010). When phosphorylated at Threonine 37/46, the binding of 4E-BP1 to the cap-
binding protein eIF4E is blocked, leading to the initiation of cap-dependent translation 
(Gingras et al., 1998). p70 S6 kinase is a mitogen activated Serine/Threonine protein 
kinase that is required for cell growth and cell cycle progression. mTORC1 
phosphorylates and activates p70 S6 kinase 1, which in turn phosphorylates the S6 
protein of the 40S ribosomal subunit and results in translation of 5' oligopyrimidine tract 
mRNAs (Kawasome et al., 1998). Besides protein translation, mTORC1 is also important 
in lipid synthesis regulation. mTORC1 may control the synthesis of lipid through the 
sterol regulatory element-binding protein (SREBP) (Porstmann et al., 2008). When 
mTORC1 is inhibited, SREBP expression is low, which decreases expression of 
lipogenic genes (Porstmann et al., 2008). mTORC1 may also stimulate SREBP activity 
through p70S6K1 activation and inhibition of lipin-1 (Kim and Chen, 2004; Laplante and 
Sabatini, 2010; Peterson et al., 2011). Furthermore, the master regulator of adipogenesis 
peroxisome proliferator-activated receptor γ (PPARγ) was reported to be a target of 
mTORC1 as well (Kim and Chen, 2004).  
In addition to synthesis of protein and lipids, mTORC1 makes a positive 
contribution to cellular metabolism and survival (Fig. 1-6). Activated mTORC1 leads to 
the upregulation of hypoxia-inducible factors (HIFs) (Cheng et al., 2014). As introduced 
before, HIF signaling pathway is the central regulator of cellular adaptation to hypoxia 
and stimulates glucose uptake and utilization through upregulating glucose transporters 
and glycolytic enzymes. Therefore, activated mTORC1 enhances glucose metabolism. 
Besides, mTORC1 directly phosphorylates and suppresses unc-51-like kinase 1 (ULK1), 
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which is required for autophagy initiation (Kim et al., 2011; Nazio et al., 2013). Thus, 
mTORC1 activation promotes cell growth through negatively regulating autophagy, 
which antagonizes the action of AMPK signaling pathway. 
6) ER stress response pathways 
Solid tumors are often challenged by insufficient supply of molecular oxygen and 
nutrients due to impaired development of vascularization, resulting in severe endoplasmic 
reticulum (ER) stress in tumor cells and consequent activation of ER stress response, 
which is also known as unfolded protein response (UPR) (Wang and Kaufman, 2014). 
Although ER stress response (or UPR) is classically linked to the protein folding stress, 
with more findings emerging, it is becoming clear that it plays a key role in many other 
fundamental and critical processes including energy homeostasis, cellular metabolism, 
cell growth and cell survival (Hetz, 2012) (Fig. 1-7). Therefore, we prefer to name it ER 
stress response instead of UPR which literally limits its function to protein folding. ER 
stress response includes the signaling crosstalk of three branches which respectively 
initiate with the activation of protein kinase R (PKR)-like endoplasmic reticulum kinase 
(PERK), inositol-requiring protein 1α (IRE1α) and activating transcription factor 6 
(ATF6). The three branches coordinately orchestrate interconnected molecular and 
cellular processes to control cell functions and behaviors (Hetz, 2012; Walter and Ron, 
2011).  
ER stress response is activated by various stressors in tumor microenvironment 
(Schroder and Kaufman, 2005; Walter and Ron, 2011). Protein folding and modification 
require the investment of ATP and related substrates such as glucose. In solid tumors, 
inadequate supply of oxygen and glucose inhibits the generation of ATP and 
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glycosylation, resulting in accumulation of unfolded and misfolded proteins (Hong et al., 
2004). The formation of disulfide bond, a major step for protein maturation, requires the 
suitable oxidative state (Malhotra and Kaufman, 2007). Thus, the imbalanced redox state 
disrupts the formation of disulfide bond and deepens protein folding burden. The 
unfolded or misfolded proteins sequester the chaperone glucose-regulated protein 78 
(GRP78, also known as BIP and HSPA5) in endoplasmic reticulum, thus dissociating the 
binding of GRP78 to PERK, IRE1α and ATF6 and in turn activating ER stress response 
(Ron and Walter, 2007a; Zhang and Kaufman, 2006).  
PERK is a type I transmembrane protein with a cytosolic serine/threonine kinase 
domain (Cui et al., 2011). Release of GRP78 from PERK results in its homodimerization 
and autophosphorylation, leading to the activation of PERK (Harding et al., 1999). 
Activated PERK phosphorylates the initiation factor eukaryotic translation initiation 
factor 2α (eIF2α) at serine 51 and attenuates the general protein translation initiation 
(Harding et al., 2000). The nuclear factor erythroid 2-related factor 2 (NRF2) is another 
downstream target of PERK and is involved in redox metabolism (Cullinan et al., 2003). 
It is also reported that the intrinsic lipid kinase activity of PERK directly phosphorylates 
diacylglycerol (DAG), which may stimulate activation of AKT and mTOR 
(Bobrovnikova-Marjon et al., 2012). When global protein translation initiation is 
inhibited, the translation of activating transcription factor 4 (ATF4) is selectively 
increased. ATF4 enters the nucleus to activate the transcription of ER stress response 
genes responsible for nutrient uptake and cellular metabolism, calcium homeostasis 
regulation, antioxidant response, cell survival and death (Singleton and Harris, 2012).  
ATF4 upregulates transcription of the growth arrest and DNA damage-inducible protein 
23 
 
34 (GADD34, also known as PPP1R15A) to direct eIF2α dephosphorylation and transmit 
negative feedback signal to ER stress response (Kojima et al., 2003). After chronic and 
severe stress, ATF4 also activates transcription of C/EBP homologous protein (CHOP; 
also known as DDIT3 and GADD153), which is reported to induce apoptosis (Han et al., 
2013). ATF4 and CHOP may also form heterodimers to upregulate genes expression for 
ER stress response feedback, mRNA translation and autophagy (Han et al., 2013).  
Like PERK, IRE1α is a type I transmembrane protein with a cytosolic 
serine/threonine kinase domain (Ron and Walter, 2007b). The dissociation of GRP78 
from IRE1α results in its homodimerization and autophosphorylation, and the activation 
of its kinase and endoribonulease activaity (Tirasophon et al., 2000). The activated IRE1α 
targets and degrades certain mRNA through regulated IRE1-dependent mRNA decay 
(RIDD) to alleviate the protein folding burden (Hollien and Weissman, 2006). RIDD also 
decreases the expression of some microRNAs (miRNAs), including miR-17, miR-34a, 
miR-96 and miR-125b, which repress caspase 2 expression, suggesting the potential role 
of IRE1α in apoptosis regulation (Upton et al., 2012). Activated IRE1α also cleaves the 
transcription factor X-box-binding protein 1 (XBP1) mRNA to initiate the removal of a 
26-base intron to produce a translational frame-shift creating an active and stable 
transcription factor termed spliced XBP1 (XBP1s) (Calfon et al., 2002). XBP1s 
translocates into nucleus and regulates the transcription of genes involved in protein 
folding (such as GRP78), trafficking, protein quality control, ER-associated protein 
degradation (ERAD), and glucose and lipid metabolism (Glimcher, 2010). Activated 
IRE1α kinase may also bind TNF receptor-associated factor 2 (TRAF2) and recruit 
different raptors to execute specific cellular functions, such as apoptosis signal-regulating 
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kinase 1 (ASK1; also known as MAP3K5) and JUN N-terminal kinase (JNK) (Urano et 
al., 2000).  
ATF6 is a type II transmembrane protein containing a cytosolic cAMP responsive 
element-binding protein (CREB)/ATF basic leucine zipper (bZIP) domain. Similar to 
PERK and IRE1α, the activation of ATF6 results from dissociation of GRP78 caused by 
accumulation of misfolded or unfolded protein (Asada et al., 2011). After release from 
the binding of GRP78, ATF6 is translocated to the Golgi apparatus through interaction 
with the coat protein II (COP II) complex for processing by the site 1 protease (S1P, also 
named MBTPS1) and site 2 protein (S2P, also named MBTPS2). The process, termed as 
regulated intramembrane proteolysis, cleaves the original 90 KD protein into a 50 KD 
active transcription factor (Haze et al., 1999; Lee et al., 2002). Active ATF6 transcription 
factor upregulates gene expression to enhance ER protein folding capacity including 
GRP78, GRP94, calreticulin, and protein disulfide-isomerase (PDI). Some studies also 
suggest that ATF6 heterodimerizes with XBP1 for induction of major ERAD components 
in response to ER stress (Asada et al., 2011).  
As mentioned above, the activation of the three branches of ER stress response 
depends on the dissociation of glucose-regulated protein 78 (GRP78) (Ni and Lee, 2007). 
GRP78 is a ubiquitously expressed protein chaperone that majorly resides in ER. It is 
both the master regulator and the major downstream target of ER stress response to adapt 
to the stressful conditions. Recently, many findings are reported demonstrating that 
GRP78 has more diverse cellular functions and locations beyond facilitating protein 
folding in ER (Lee, 2007). GRP78 overexpression is also widely revealed in cancer cell 
lines and is associated with tumor progression and metastasis (Lee, 2007; Miao et al., 
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2013). More evidence is emerging to indicate that GRP78 is a promising therapeutic 
target for cancer diagnosis and therapy. 
GRP78 was first discovered in the mid-1970 as constitutively expressed protein in 
response to glucose starvation or protein glycosylation inhibition (Ni et al., 2011). 
GRP78 was once identified as an immunoglobulin heavy chain-binding protein (BiP), but 
then GRP78 and BiP were demonstrated to be identical, leading to the designation of 
GRP78 as an ER protein chaperone (Gonzalez-Gronow et al., 2009). As a protein 
chaperone, GRP78 facilitates protein folding, protein quality control and degradation in 
ER. GRP78 also functions as the pivotal regulator of ER stress response by binding and 
inhibiting PERK, IRE1α and ATF6. When unfolded or misfolded proteins accumulate in 
ER, GRP78 is dissociated to facilitate protein folding and ER stress response pathways 
are consequently activated (Wang et al., 2009).  
Recent advances report that GRP78 has more ER stress response-independent 
biological functions, particularly in tumor cells (Ni et al., 2011). GRP78 expression is 
associated with proliferative rates of several human tumor cell lines; and knockdown of 
GRP78 by small interfering RNA reduces tumor cell growth (Pyrko et al., 2007). 
Homologous knockout of GRP78 embryos in mice causes peri-implantation lethality 
(Dong et al., 2008). The precise mechanism underling GRP78 promotes tumor cell 
proliferation is still obscure. One possible explanation is that GRP78 binds and stables 
WNT and stimulates WNT-β-catenin proliferative signaling (Verras et al., 2008). 
Another inspiring hypothesis is that GRP78 may facilitate cell proliferation because of its 
cell surface localization. After transported to cell surface by the carrier protein MTJ1 in 
macrophages and tumor suppressor prostate apoptosis response 4 (PAR4) in prostate cell 
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lines, GRP78 acts as a signal receptor to mediate cell survival and proliferation (Misra et 
al., 2005; Zhang et al., 2010). For instance, in prostate cancer cells, GRP78 binds the 
active form of the plasma proteinase inhibitor α2-macroglobulin (α2M), thus activating 
ERK and AKT to promote cell proliferation and inhibit apoptosis (Misra et al., 2002). 
Cell surface GRP78 was reported to interact with Cripto (also known as teratocarcinoma-
derived growth factor 1) to stimulate the activation of MAPK and PI3K signaling 
pathway, which promotes tumor cell proliferation (Wey et al., 2012). In addition, GRP78 
functions as the suppressor of apoptosis (Luo and Lee, 2013). GRP78 was observed in a 
complex with caspase 7 to protect cells from apoptosis triggered by etoposide (Reddy et 
al., 2003). GRP78 was also discovered to be associated with mitochondria to maintain 
mitochondria permeability and protect against ER-stress-induced apoptosis (Shu et al., 
2008). Furthermore, GRP78 is found to be required for stress-induced autophagy to 
prevent cell death through an unclear mechanism (Li et al., 2008). Therefore, GRP78 has 
crucial pro-proliferation and anti-apoptosis functions in tumor cells.  
Extensive studies have revealed that GRP78 overexpression in cancer cells 
confers resistance against cancer therapies, including radiation therapy and anti-cancer 
chemical drugs (Koomagi et al., 1999; Lee, 2007). In endoplasmic reticulum, GRP78 acts 
as the ER stress response regulator and executor to facilitate cellular adaptation to ER 
stress and cell survival. Beyond ER, GRP78 at various cellular locations stimulates cell 
proliferation and inhibits cell death through interaction with diverse effectors. However, 
many mechanisms underlying GRP78 functions and its translocations still remain unclear. 
A better understanding for GRP78 biology will allow for the discovery and development 
of promising methods for cancer diagnosis and treatment.  
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7). Autophagy and apoptosis 
Autophagy and apoptosis are two important pathways to regulate cell survival and 
death. In a mildly stressful microenvironment with hypoxia or insufficiency of energy 
and nutrients, one critical cellular protective mechanism is macroautophagy (referred as 
“autophagy”) (Kaur and Debnath, 2015). Under the nutrient-insufficient conditions, 
AMPK pathway is activated and mTOR pathway is inhibited, which coordinately 
phosphorylates ULK1 which initiates autophagy. When autophagy is initiated, double-
membrane vesicles called autophagosomes are generated with the involvement of LC3B.  
Autophagosomes sequester and deliver damaged or harmful macromolecules and 
organelles to lysosomes for breaking down to maintain energy and nutrient homeostasis 
(He and Klionsky, 2009; Mizushima, 2007). As an important response for cell adaption to 
stressful microenvironment, ER stress response also takes participation in the regulation 
of autophagy and apoptosis. It has been reported that through ATF4 severe hypoxia 
induces expression of the essential autophagy effector LC3B (B'chir et al., 2013; 
Rouschop et al., 2010), and splicing of XBP1 mRNA was reported to induce initiation of 
autophagy through upregulating BECLIN1 expression (Margariti et al., 2013), indicating 
hypoxia-induced ER stress response plays a role in activating autophagy. As a result, 
autophagy promotes cellular adaptation to nutrient-insufficient conditions and facilitates 
cell survival (Figure 1-8). When the stressful condition is persistent and exceeds an 
intensity threshold, another type of programmed cell death (PCD) apoptosis is activated 
(Elmore, 2007). Apoptosis is characterized by a series of typical biochemical changes, 
including mitochondrial outer membrane permeabilization (MOMP), activation of 
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apoptotic effector caspases and activation of catabolic hydrolases, which degrade 
majority of macromolecules in the cell and finally induce cell death (Portt et al., 2011) 
(Figure 1-9). ATF4 induces transcription of the proapoptotic transcription factor CHOP 
(Kato et al., 2012; Tabas and Ron, 2011), suggesting ER stress response also takes a part 
in activation of apoptosis. Autophagy and apoptosis are often activated by similar 
stressors with different severity, and cause opposing consequences. Autophagy 
constitutes an adaptive strategy to facilitate cell survival, while apoptosis finally triggers 
cell death in response to lethal stressors (Fig. 1-10) (Nikoletopoulou et al., 2013). 
Therefore, autophagy and apoptosis mutually inhibit each other to determine cell fate 
(Maiuri et al., 2007). As ER stress response is involved in regulation of both autophagy 
and apoptosis. How ER stress response balances activation of autophagy and apoptosis 
under physiologically hypoxic condition is an intriguing question but still remains 
unclear.       
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Figure 1-1. Hypoxia in solid tumor tissues. 
Oxygen is transported by red blood cells in blood flow and diffused to different areas. 
Vascularization is defectively developed and blood vessels are unevenly distributed in 
solid tumors. As a consequence, oxygen concentration in the areas decreases dramatically 
with the distance to the blood vessels increasing. Therefore, tumor cells in these distant 
areas suffer from hypoxia, or anoxia. 
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Figure 1-2. Ischemia in normal tissues causes hypoxia. 
Blood clots may block the blood flow, leading to ischemia in normal tissues, which in 
turn decreases the oxygen concentration in these regions and results in hypoxia.  
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Figure 1-3. The Pasteur effect and Warburg effect in hypoxia and tumors. 
Pasteur effect and Warburg effect are the two most studied metabolic alterations in 
hypoxia and tumor cells. Both are associated with enhanced glycolysis and lactate 
fermentation to recycle NAD+. 
 
 
 
 
 
Warburg effect 
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Figure 1-4. The metabolic roles of pyruvate in NAD+ recycling and biosynthesis. 
Schematic summary of pyruvate-participated metabolic pathways. Pyruvate may accept 
electron and be reduced in lactate fermentation to recycle NAD+. In addition to serving as 
electron acceptor, pyruvate may be used as a substrate in the synthesis of various 
metabolites, including acetyl-CoA, α-ketoglutarate (α-KG), succinate, oxaloacetate 
(OAA), alanine and aspartate. These metabolites can be used for the synthesis of proteins, 
lipids or nucleotides, thus supporting cell proliferation.   
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Figure 1-5. The AMP-activated protein kinase (AMPK) pathway. 
AMPK pathway plays a critical role in the regulation of energy status. The insufficiency 
of nutrients decreases ATP generation and increases the ratio of AMP to ATP. AMP 
binds to the γ subunit of AMPK, leading to a conformational change and the consequent 
phosphorylation and activation of AMPK at Thr172 by the serine/threonine kinase LKB1. 
AMPK inhibits the synthesis of protein and lipid through inhibition of mTOR and ACC 
to decrease energy consumption. AMPK can also induce autophagy through the 
phosphorylation and activation of ULK1.   
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Figure 1-6. Mechanistic target of rapamycin (mTOR) pathway. 
Mechanistic target of rapamycin (mTOR) pathway is a critical regulator of protein 
translation and cell growth. Under sufficient nutrients, mTOR is phosphorylated and 
activated by several upstream regulators such as PI3K/AKT. Activated mTOR pathway 
induces the translation of protein through phosphorylating downstream substrates 
p70S6K and 4E-BP1. mTOR also crosstalks with AMPK to inhibit the initiation of 
autophagy through regulating ULK1 and ATG14. Active mTOR also translationally 
upregulates HIF1, facilitating transformation of cellular metabolism. However, when 
nutrient levels are low, mTOR pathway is inhibited by TSC1/2 and AMPK. Therefore, 
mTOR pathway is the master regulator of energy homeostasis and biosynthesis.  
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Figure 1-7. ER stress responses. 
Under the conditions of nutrient insufficiency, protein folding is impaired and unfolded 
proteins are accumulated. GRP78 is competitively recruited by unfolded proteins, thus 
activating PERK, ATF6 and IRE1α. Activated PERK phosphorylates eIF2α, which 
inhibits the global translation of proteins and selectively upregulates translation of ATF4. 
Activated ATF6 is translocated to Golgi and cleaved to be the active 50 KD protein 
fragment. Activated IRE1α, as an endonuclease, induces a global mRNA decay and 
specific splicing of XBP1. ATF4, 50 KD fragment of ATF6, and spliced XBP1 
coordinately facilitate the cellular adaption to the original stress that triggers the ER 
stress response. 
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Figure 1-8. Nutrient insufficiency triggers autophagy. 
The nutrient-insufficient conditions lead to phosphorylation of the autophagy initiator 
ULK1 through activating AMPK pathway and inhibiting mTOR pathway, thus inducing 
the formation of autophagosome with the involvement of BECLIN1 and LC3B. 
Autophagosomes sequester and deliver damaged or harmful macromolecules and 
organelles to lysosomes for breaking down. ER stress response regulates autophagy 
through the effectors ATF4 and spliced XBP1. Specifically, ATF4 induces expression of 
the essential autophagy effector LC3B and spliced XBP1 upregulates BECLIN1 
expression. 
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Figure 1-9. Severe nutrient insufficiency activates apoptosis. 
Severe nutrient-insufficient conditions induce activation of BH3-only proteins to initiate 
apoptosis. The consequent mitochondrial outer membrane permeabilization (MOMP) 
causes release of cytochrome c, which induces activation of apoptotic effector caspases, 
thus degrading majority of macromolecules in the cell and finally inducing cell death. ER 
stress response may regulate apoptosis through the pro-apoptotic transcription factor 
CHOP, which activates some BH3-only proteins and inhibits Bcl2, a negative regulator 
of apoptosis. 
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Figure 1-10. Autophagy and apoptosis coordinately regulate cell survival and death. 
Under the conditions of nutrient insufficiency, autophagy and apoptosis are activated 
depending on the stress severity. The AMPK pathway, mTOR pathway or ER stress 
response may participate in these processes. Mild stress activates autophagy to facilitate 
cell adaption, and severe and prolonged stresses activate apoptosis and cause cell death. 
Autophagy and apoptosis reciprocally inhibit each other to determine cell fate. 
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Chapter 2: Exogenous pyruvate facilitates hypoxic cell adaptation by serving as an 
oxygen surrogate 
 
 
1) Abstract 
Molecular oxygen is the final electron acceptor in cellular metabolism but cancer 
cells often become adaptive to hypoxia, which promotes resistance to chemotherapy and 
radiation. The reduction of endogenous glycolytic pyruvate to lactate is known as an 
adaptive strategy for hypoxic cells. Whether exogenous pyruvate is required for hypoxic 
cell proliferation by either serving as an electron acceptor or a biosynthetic substrate 
remains unclear. By using both hypoxic and ρ0 cells with defective electron transfer chain, 
I show that exogenous pyruvate is required to sustain proliferation of both cancer and 
non-cancer cells that cannot utilize oxygen. Particularly, I show that absence of pyruvate 
led to glycolysis inhibition and AMPK activation along with decreased NAD+ levels in ρ0 
cells; and exogenous pyruvate increases lactate yield, elevates NAD+/NADH ratio and 
suppresses AMPK activation. Knockdown of lactate dehydrogenase significantly inhibits 
the rescuing effects of exogenous pyruvate. In contrast, none of pyruvate-derived 
metabolites tested (including acetyl-CoA, α-ketoglutarate, succinate and alanine) can 
replace pyruvate in supporting ρ0 cell proliferation. Knockdown of pyruvate carboxylase, 
pyruvate dehydrogenase and citrate synthase do not impair exogenous pyruvate to rescue 
ρ0 cells. Importantly, I show that exogenous pyruvate relieves ATP insufficiency and 
mTOR inhibition and promotes proliferation of hypoxic cells, and that well-oxygenated 
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cells release pyruvate, providing a potential in vivo source of pyruvate. Taken together, 
my data support a novel pyruvate cycle model in which oxygenated cells release pyruvate 
for hypoxic cells as an oxygen surrogate. The pyruvate cycle may be targeted for a new 
therapy of hypoxic cancers. 
 
2) Introduction 
Cell survival, proliferation and other cellular functions require constitutive supply 
of molecular oxygen and nutrients to maintain ATP production, redox homeostasis, and 
biosynthesis (Boroughs and DeBerardinis, 2015; Cairns et al., 2011b; Hanahan and 
Weinberg, 2011). However, cells in ischemic lesions and solid tumors commonly suffer 
from hypoxia (Brown and Giaccia, 1998; Jain, 2005; Kim et al., 2009; Vaupel et al., 
1992). Hypoxia not only impairs mitochondrial respiration and decreases ATP 
production, but also causes accumulation of NADH along with NAD+ depletion 
(Papandreou et al., 2006; Wilson et al., 1977). It has also been reported that hypoxia leads 
to formation of excessive reactive oxygen species (ROS), particularly superoxide, 
causing oxidative stress (Guzy et al., 2005; Hernansanz-Agustin et al., 2014b; Waypa et 
al., 2010).   
 
The best known adaptive mechanism of hypoxic cells, the Pasteur effect, is 
mainly mediated by hypoxia-inducible factors (HIFs). Particularly, HIF-1 
transcriptionally reprograms glucose metabolism, shifting ATP production from oxygen-
dependent oxidative phosphorylation to NAD+-dependent glycolysis (Kim et al., 2006b; 
Semenza, 2003a). Hypoxia activates HIF-1 functions and transcriptionally upregulates 
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the expression of glucose transporters, glycolytic enzymes and regulatory proteins of 
glycolysis. The elevated glycolysis maintains ATP levels in hypoxic cells, facilitating cell 
survival and other functions in the hypoxic microenvironment (Ivan et al., 2001; Lu et al., 
2002a; Lum et al., 2007a). HIF-1-stimulated expression of lactate dehydrogenases (LDH) 
accelerates the conversion of endogenous pyruvate generated from glycolysis to lactate, 
recovering NAD+ by accepting electrons from NADH, thus maintaining a continuous 
glycolysis without complete NAD+ exhaustion (Benita et al., 2009; Firth et al., 1995).   
 
In addition to hypoxia, defective ETC blocks oxygen utilization in oxidative 
phosphorylation. Since a functional ETC depends on 13 proteins encoded by the 
mitochondrial genome (Chen and Butow, 2005), cells depleted of mitochondrial DNA (ρ0 
cells) cannot use molecular oxygen as the final electron acceptor for cellular respiration, 
providing a unique model to study cellular adaptation to defective oxygen utilization 
(Shen et al., 2003). Interestingly, the ETC-defective ρ0 cells absolutely depend on 
exogenously supplemented pyruvate for survival and proliferation (King and Attardi, 
1989, 1996), indicating that exogenous pyruvate, in addition to pyruvate endogenously 
generated from glycolysis, plays a critical role in cells that cannot use molecular oxygen.  
 
Pyruvate is a critical node in multiple metabolic pathways for both biosynthesis 
and NAD+ homeostasis (Roudier and Perrin, 2009; Yin et al., 2012a). However, the 
precise role of exogenous pyruvate that is critical for cell adaptation to hypoxia remains 
unclear. In this chapter, using both cancer and non-cancer cells, I demonstrate that 
endogenous pyruvate from glycolysis is insufficient to support continuous ATP 
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production in cells with severe deficiency in oxygen utilization. Exogenous pyruvate is 
required to support the survival and proliferation of hypoxic cells mainly by acting as an 
oxygen surrogate to accept electrons, thus maintaining NAD+ homeostasis. The 
biosynthetic role of pyruvate as a carbon source is generally dispensable in cell 
proliferation. Furthermore, I show that well-oxygenated cells release pyruvate. My data 
suggest a model that well-oxygenated cells secrete pyruvate to support the survival and 
proliferation of hypoxic cells, which uptake exogenous pyruvate as an oxygen surrogate 
in redox metabolism, thus facilitating ATP homeostasis and hypoxic adaptation. 
 
3) Materials and methods 
 Cell culture 
 
HeLa and Hep3B were purchased from ATCC (Chicago, IL). H9c2 was a kind gift 
from Dr. P. Lelkes (Temple University, Philadelphia, PA). 143B and 143B206 were kind 
gifts from Dr. M. King (Thomas Jefferson University, Philadelphia, PA). All cell lines 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 25 mM 
glucose, 1 mM pyruvate and 4 mM glutamine supplemented with 10% fetal bovine serum 
(FBS), unless otherwise indicated. The culture medium for 143B206 cells was further 
supplemented with 50 μg/mL uridine. All cells were cultured in humidified 5% CO2/95% 
air atmosphere at 37°C. For pyruvate-deprivation study, cells were cultured in pyruvate-
free DMEM with 25 mM glucose, 4 mM glutamine and 10% dialyzed FBS. Hypoxia 
treatement were carried out by culturing cells directly in a hypoxic Workstation (Invivo2 
300, Ruskinn Technology, Sanford, ME) equipped with a programmable controller of 
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humidity, temperature and premixed gas (2% O2, 5% CO2, balanced with N2).  
 
Cell proliferation assay  
 
Cell proliferation rates were determined by CyQUANT® NF Cell Proliferation 
Assay Kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. In brief, 
cells were plated at density of 100-500 cells per well in a 96-well microplate. Cell 
numbers in wells were measured every one or two days. Culture medium was removed 
gently, 50 μL of CyQUANT® NF dye solution (which exhibits strong fluorescence 
enhancement after binding with DNA) was added to the well and then the microplate was 
covered and incubated at 37°C for 30 min. The fluorescence intensity was measured 
using a fluorescence microplate reader with excitation at 485 nm and emission detection 
at 530 nm. As DNA content is closely proportional to cell number, the assay is designed 
to produce a linear analytical response from at least 100-20,000 cells per well in a 96-
well microplate. The relative cell number stands for the ratio of cell number at indicated 
time to the starting cell number at the time of treatment. 
 
Microscopy analysis of living cell morphology 
 
143B and 143B206 cells were seeded in 6-well culture plates and cultured in the 
medium with 1 mM pyruvate or not for 48 h. Images of the living cells were 
photographed under inverted Axioplan phase-contrast microscope (Zeiss, Thornwood, 
NY) at 400 × magnification, and analyzed with the software Slidebook6 (3i, Denver, CO). 
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Extracellular acidification rate (ECAR) 
 
ECAR was measured using Seahorse XF24 extracellular Flux analyzer (Seahorse 
Bioscience, North Billerica, MA) following the manufacturer’s instructions. In brief, 
143B and 143B206 cells were seeded at a density of 2×104 and 3×104 cells/well 
respectively into Seahorse 24-well microplates and allowed to grow for 18 h. Thirty 
minutes before the assay, the culture medium was replaced with unbuffered XF assay 
medium (pH7.4) supplemented with 25 mM glucose and 1 mM or 0 mM pyruvate, and 
incubated at 37°C for 30 minutes for stabilization of pH and temperature. After all the 
measurements were completed, cells were treated with trypsin and counted. These cell 
counts were used to normalize ECAR.  
 
ATP concentration assay  
The ATP concentrations in cells were determined with ATP Determination Kit 
(Thermo Fisher Scientific) based on the manufacturer’s protocol and literature (Schafer et 
al., 2009). Briefly, cells were plated in 60 cm culture dishes and cultured overnight. Then 
the cells were treated with indicated conditions. After 24 hours of treatment cells were 
lysed in 1% NP40 (plus protease inhibitors) and centrifuged at 14,000 rpm for 15 min. 
The supernatant was collected as cell lysates for ATP assay. Protein concentrations in 
lysates were measured with Bio-Rad Protein Assay Dye Reagent Concentrate. ATP levels 
were normalized by protein concentrations. 
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NAD+ and NADH assay 
 
Intracellular NAD+ and NADH levels were determined with the Fluoro 
NAD/NADHTM Detection Kit (Cell Technology, Mountain View, CA) according to the 
manufacturer’s protocol. Briefly, 143B and 143B206 cells were seeded at a density of 
2×106 and 3×106 cells into a 10 cm culture dish respectively and cultured under 21% or 2% 
oxygen with 0 mM or 1 mM pyruvate for 24 h. Cells were harvested and lysed with 
provided lysis buffer. The lysates were then centrifuged at 8,000 rpm for 5 min at 4 °C. 
The supernatant was retrieved for subsequent NAD+ and NDAH measurement with 
excitation 530-570 nm/emission 590-600 nm fluorescent assay. The NAD+/NADH ratio 
was then calculated. A parallel culture dish of both cells were cultured under the same 
condition and then counted for normalization of NAD+ levels.  
 
Knockdown with siRNA 
 
Knockdown of pyruvate carboxylase (PC) (EC number: 6.4.1.1), pyruvate 
dehydrogenase (lipoamide) alpha 1 (PDHA1) (EC number: 1.2.4.1), citrate synthase (CS) 
(EC number: 2.3.3.16), and lactate dehydrogenase A (LDHA) (EC number: 1.1.1.27) 
were performed using the specific Invitrogen Silencer® Select siRNAs (PC siRNA ID: 
s10089, PDHA1 siRNA ID: s10245, CS siRNA ID: s3583, LDHA siRNA ID: s351). 
Silencer® Select Negative Control siRNA served as negative control. LipofectamineTM 
2000 Transfection Reagent (Invitrogen) was used for the transfection of siRNAs. Briefly, 
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cells were seeded into a 60-mm culture dish and were allowed to achieve 95% confluence. 
200 pmol siRNA and 6 μL Lipofectamine 2000 Transfection Reagent were incubated in 
0.5 mL Gibco Opti-MEM® I Reduced-Serum Medium (Thermo Fisher Scientific) for 5 
min, respectively, and then mixed and incubated for 20 min. Cells were transfected with 
the mixed medium. 6 h after transfection, cells were seeded in 96-well microplates for 
cell proliferation assay, and in 60-mm culture dishes for RNA and protein extraction. 
 
Quantitative real-time PCR (qRT-PCR)  
 
Total RNA was extracted with Qiagen RNeasy kit (Invitrogen). cDNA was 
synthesized using SuperScript II Reverse Transcriptase (Invitrogen), and then used for 
quantitative analysis with specific TaqMan probes for PC (Hs00559398_m1), PDHA1 
(Hs01049345_g1), CS (Hs02574374_s1) and β-actin (Hs01060665_g1) in StepOnePlus 
Real-Time PCR System (Applied Biosystems, Foster City, CA). cDNA was amplified in 
20 μL reactions containing 1 μL of probe and 10 μL of 2 × Taqman® Gene Expression 
Master Mix (Applied Biosystems). The procedure applied was 50 °C for 2 min and 95 °C 
for 10 min at Stage 1, 95 °C for 15 s and 60 °C for 1 min for 40 cycles at Stage 2. Data 
were quantitatively analyzed by the software StepOneTM v2.1 (Applied Biosystems) with 
comparative CT method. β-actin was used as endogenous control. All genes were 
analyzed in triplicates.  
 
Immunoblotting  
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Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% 
Sodium deoxycholate, 0.1% SDS and 1% NP-40), homogenized and centrifuged at 
14,000 rpm for 15 min. The supernatant was collected as whole cell lysates. Protein 
concentrations in the lysates were measured with Bio-Rad Protein Assay Dye Reagent 
Concentrate (BIO-RAD, Hercules, CA). 30 μg of proteins were separated by 8% SDS-
PAGE, transferred to PVDF membrane (BIO-RAD), and probed with specific primary 
antibodies including rabbit anti-phospho-acetyl-CoA carboxylase (Ser79) (Catalog # 
11818S), rabbit anti-acetyl-CoA carboxylase (Catalog # 3662S), rabbit anti-LDHA 
(Catalog # 3582S), rabbit anti-phospho-mTOR (Ser2448) (Catalog # 5536S), rabbit anti-
mTOR (Catalog # 2983S), rabbit anti-phospho-4E-BP1 (Thr37/46) (Catalog # 2855S), 
and rabbit anti-4E-BP1  (Catalog # 9452S) from Cell Signaling, mouse anti-pyruvate 
carboxylase (Catalog # sc-271493), mouse anti-PDHA1 (Catalog # sc-377092), mouse 
anti-citrate synthase (Catalog # sc-390693) from Santa Cruz, and mouse anti-α-tubulin 
(Catalog # T9026, Sigma). The primary antibodies were detected with appropriate 
secondary antibody including horseradish peroxidase-conjugated goat anti-mouse 
(catalog #A4416) or goat anti-rabbit (catalog #A6154) from Sigma and developed with 
SuperSignal® West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). The 
detected bands were quantified with ImageJ (NIH, Bethesda, MD). 
 
Pyruvate concentration assay  
 
Cells were cultured in 6-well plates with 2 mL culture media in each well. Culture 
medium was replaced with pyruvate-free DMEM supplemented with 10% dialyzed FBS 
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and 50 µM pyruvate, and then the cells were cultured in 2% O2 at 37 °C for 24 h. An 
aliquot of incubation medium was subsequently collected for measurement of pyruvate 
concentration with the Pyruvate Assay Kit (Eton Bioscience, San Diego, CA) according 
to the manufacturer’s instruction.  
 
Data analysis  
 
Data in the figures are presented as mean values ± SD. Student’s t-test and 
multivariate analysis of variance were used for statistical analysis with GraphPad Prism 
6.0 (GraphPad Software, San Diego, CA). Differences in all the tests were considered as 
statistically significant at p value < 0.05. 
 
4) Results 
 
Exogenous pyruvate is required to support the proliferation of ETC-defective cells. 
 
To investigate the biochemical roles of exogenous pyruvate in cellular adaptation 
to defective utilization of oxygen, I exploited the metabolic properties of the ρ0 143B206 
cell line (King and Attardi, 1989). The glycolysis and pyruvate metabolism in this cell 
line were outlined in Fig. 2-1. The 143B206 cell line is derived from 143B through 
chronic exposure to ethidium bromide (EtBr), which disrupted the replication of 
mitochondrial genome (King and Attardi, 1989). Mitochondrial genome encodes 13 
proteins that are components of Complex I, III, IV and V in ETC (Mercer et al., 2011; 
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Schon et al., 2012). Due to lack of mitochondrial DNA, 143B206 cells have no functional 
ETC and, like anoxic cells, exclusively rely on glycolysis and lactate fermentation for 
ATP production and homeostasis of NAD+/NADH (Pallotti et al., 2004). For glycolysis of 
one glucose molecule, two molecules of NAD+ need to be reduced to 2 molecules of 
NADH, which consume two molecules of pyruvate generated endogenously from 
glycolysis in lactate fermentation (Fig. 2-1). Therefore, based on stoichiometry all 
endogenous pyruvate generated from glycolysis in 143B206 cells would be converted to 
lactate, simplifying the analysis of the role of exogenous pyruvate.  
 
Firstly, I investigated the effects of different concentrations of pyruvate on 
proliferation of 143B206 cells. Without exogenous pyruvate the growth of 143B206 cells 
was inhibited, which is consistent with the previous report (King and Attardi, 1989), but 
0.2 mM pyruvate was sufficient to significantly promote the proliferation of 143B206 
cells (Fig. 2-2A). Because 143B206 cells had the highest proliferation rate in the 
presence of 1 mM pyruvate, I chose 1 mM as the pyruvate concentration in the following 
experiments (Fig. 2-2B). I then compared the proliferation of 143B206 cells and the 
parental 143 cells in the presence or absence of 1 mM pyruvate. Under normoxic 
conditions (21% O2) exogenous pyruvate did not affect the proliferation of 143B (Fig. 2-
3A). However, ETC-defective 143B206 cells failed to proliferate in pyruvate-free media, 
which was rescued by addition of 1 mM pyruvate (Fig. 2-3B). I also determined the 
morphological change of 143B206 cells with light microscopy. After 48 h of pyruvate 
withdrawal there was no visible morphological change in 143B206 cells, but cell 
proliferation was inhibited. As a control, the parental 143B cells maintained persistent 
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and rapid proliferation regardless of the addition of exogenous pyruvate (Fig. 2-4). These 
data further confirmed the dependence of 143B206 on exogenous pyruvate for 
proliferation. 
 
Exogenous pyruvate acts as the electron acceptor in ETC-defective cells. 
  
The well-known role of pyruvate in Pasteur and Warburg effect in cancer 
metabolism is to accept electrons from NADH, being reduced to lactate by lactate 
dehydrogenase (LDH).  I asked whether the critical role of exogenous pyruvate in 
supporting 143B206 proliferation is to maintain NAD+ homeostasis. In order to examine 
the metabolic activity in both 143B206 and 143B cell lines, I first utilized the Seahorse 
metabolic analyzer to measure extracellular acidification rate (ECAR), the indicator of 
lactate formation (Fig. 2-5A and B). The parental 143B cells cultured with 21% O2 
maintained an ECAR at 21 ± 1.32 mpH/min/104 cells, which was not affected by the 
addition of exogenous pyruvate (Fig. 2-5C). On the other hand, the ETC-defective 
143B206 cells showed an ECAR value at 9 ± 1.27 mpH/min/104 cells in the absence of 
exogenous pyruvate, indicating that glycolysis was inhibited but not stimulated. 
Importantly, addition of exogenous pyruvate dramatically increased the ECAR to 23 ± 
1.04 mpH/min/104 cells (Fig. 2-5C), indicating that exogenous pyruvate promotes lactate 
generation. I also compared the oxygen utilization in 143B and 143B206 cells in the 
presence or absence of pyruvate. 143B cells showed typical OCR profiles similar to other 
cancer cells. 143B206 cells had no significant amount of oxygen consumption, which 
was not affected by the presence of exogenous pyruvate, further confirming that ETC is 
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deficient in 143B206 cells (Fig. 2-6).  
 
             A major direct metabolic consequence of lactate generation is the oxidation of 
NADH to NAD+ (Canto et al., 2015). To investigate the effect of exogenous pyruvate on 
intracellular NAD+ levels and NAD+/NADH ratios, I cultured 143B and 143B206 cells 
under conditions specified in Fig. 2-7. The parental 143B cells had an NAD+ level of 
189.80 ± 0.03 pMoles/106 cells. Hypoxia decreased NAD+ level to 118.06 ± 0.16 
pMoles/106 cells which was restored by exogenous pyruvate (Fig. 2-7A). In comparison, 
the ETC-defective 143B206 had a dramatically lower NAD+ level at 15.39 ± 0.01 
pMoles/106 cells, and addition of exogenous pyruvate significantly elevated the NAD+ 
level to 32.21 ± 0.03 pMoles/106 cells. The elevated NAD+ level remained lower than 
that of the parental cells. Consistently, 143B cells maintained NAD+/ NADH ratio at 3.46 
± 0.17 under normoxia. Hypoxia decreased the NAD+/NADH ratio to 2.66 ± 0.10, which 
was prevented by the addition of exogenous pyruvate (Fig. 2-7B). Since 143B206 cells 
have no functional ETC, the NAD+/NADH ratio maintained at a low level (0.14 ± 0.003), 
and the availability of oxygen showed no effect on the ratio (Fig. 2-7C). However, 
addition of exogenous pyruvate significantly increased the NAD+/NADH ratios under 
both normoxic and hypoxic conditions (Fig. 2-7C).  
 
LDHA encodes one subunit of LDH, which can be induced by hypoxia, and has 
been considered as part of the cellular adaptive mechanism to hypoxia (Iyer et al., 1998). 
To further confirm the critical role of pyruvate as an oxygen surrogate, I knocked down 
LDHA in 143B206 cells and assayed the growth curve in the presence of 1 mM pyruvate. 
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Transfection of LDHA siRNA in 143B206 cells significantly decreased the protein level 
of LDHA (Fig. 2-8A) and led to a slowdown of ECAR (Fig. 2-8B). Accompanied by the 
decrease of LDHA protein level and ECAR, the proliferation rate of 143B206 cells 
decreased significantly in the presence of pyruvate (Fig. 2-8C).  
 
Considering ETC-defective 143B206 cells showed inhibited glycolysis, I next 
investigated the effect of exogenous pyruvate on ATP status. ATP levels were measured in 
143B and 143B206 cells under 21% O2 with or without 1 mM pyruvate. I observed that 
exogenous pyruvate had no obvious effect on ATP levels in 143B cells, but ATP level in 
143B206 cells with absence of exogenous pyruvate was very low (1.04 ± 0.14 μmoles/g 
protein), which was significantly increased by exogenous pyruvate (Fig. 2-9A).  AMP-
activated protein kinase (AMPK) senses AMP levels and is activated upon ATP depletion 
(Mihaylova and Shaw, 2011a). One of the best known direct targets of AMPK is acetyl-
CoA carboxylase (ACC), which is inhibited by AMPK-catalyzed phosphorylation, thus 
being used as a cellular marker for ATP status (Tomas et al., 2002). Under normoxic 
conditions, phosphorylated ACC was not detectable in 143B cells but was easily detected 
in 143B206 cells (Fig. 2-9B). As I predicted, addition of exogenous pyruvate 
significantly decreased the level of phosphorylated ACC without altering the total levels 
of ACC (Fig. 2-9B). 
 
Taken together, these data indicate that exogenous pyruvate rescues 143B206 cell 
by maintaining the homeostasis of intracellular NAD+, which is the determining factor of 
survival and proliferation of 143B206 cells. These data also imply that under severe 
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hypoxia, exogenous pyruvate is needed to serve as an oxygen surrogate to maintain 
minimal NAD+ levels, thus ensuring the continuation of glycolysis. 
 
Rescuing effects of pyruvate-derived metabolites on 143B206 proliferation. 
 
Pyruvate is a pivotal node in cellular carbon metabolism, contributing carbon to 
the synthesis of various metabolites, including acetyl-CoA, α-ketoglutarate (α-KG), 
succinate, oxaloacetate (OAA), alanine (Ala) and aspartate (Asp) (Fig. 1-4). To determine 
if any of those pyruvate-derived metabolites are rate-limiting metabolites in 143B206 cell 
proliferation, I used each of those metabolites to replace pyruvate and examined if it can 
rescue 143B206. Acetoacetate can be converted to acetyl-CoA by acetoacetate succinyl-
CoA transferase and thiolase. Since acetoacetate, α-KG, succinate and OAA cannot 
diffuse across the cell membrane effectively, I exploited their modified precursors ethyl-
acetoacetate, dimethyl-α-KG, dimethyl-succinate and diethyl-OAA. The alkyl groups can 
be hydrolyzed and removed by intracellular esterase after entering the cells (Doucette et 
al., 2011; Khan et al., 1996; Wise et al., 2008). I observed that the addition of Ala, acetyl-
CoA, α-KG and succinate could not replace exogenous pyruvate to support 143B206 cell 
proliferation (Fig. 2-10). OAA and aspartate partially rescued the proliferation of 
143B206 cells; however, their rescuing effects were significantly lower than exogenous 
pyruvate (Fig. 2-10).  
 
Suppression of the biosynthesis of OAA, acetyl-CoA and citrate does not impair the 
rescuing effect of exogenous pyruvate. 
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The major biosynthetic role of pyruvate is to serve as a substrate for the 
biosynthesis of OAA (by pyruvate carboxylase, PC) and acetyl-CoA (by pyruvate 
dehydrogenase complex, PDC). OAA may serve as the α-keto acid for the synthesis of 
aspartate, which is needed for protein translation and synthesis of nucleotides as well as 
asparagine. More importantly, OAA and acetyl-CoA can be further used in the 
biosynthesis of citrate by citrate synthase (CS), which is the starting step of Krebs cycle 
(Fig. 1-4). Since biosynthesis of membrane phospholipids and cholesterols depends on 
the citrate synthesis, I examined if facilitating the synthesis of OAA and citrate for 
proliferative biosynthesis underlines the importance of exogenous pyruvate. I knocked 
down PC, PDHA1 (a critical subunit of PDC) and CS in 143B206 cells, and observed 
knockdown of these enzymes did not impair the proliferation of 143B206 cells in the 
presence of exogenous pyruvate (Fig. 2-11, 12 and 13). Interestingly, CS knockdown 
even slightly, but significantly promoted 143B206 proliferation (Fig. 2-13). These data 
indicate that the critical role of exogenous pyruvate to rescue ETC-defective cells is not 
to act as a substrate to support biosynthesis of OAA or lipids. 
 
Exogenous pyruvate relieves ATP depletion stress and enhances the proliferation of 
cells under hypoxic conditions. 
 
 Similar to ETC deficiency, prolonged hypoxia may lead to NADH accumulation 
and NAD+ depletion, thus eventually inhibiting glycolysis and ATP production. To 
determine the effect of exogenous pyruvate on ATP sufficiency and proliferation of 
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prolonged hypoxic cells, I cultured 143B, HeLa, Hep3B and H9c2 cell lines under 
indicated conditions and evaluated the ATP levels, AMPK activity and proliferation rates 
of these cell lines. Hypoxia significantly decreased ATP levels in all the four cell lines, 
and exogenous pyruvate acted against hypoxia to increase ATP levels. Interestingly, 
exogenous pyruvate also increased ATP levels under normoxic conditions in HeLa, 
Hep3B and H9c2 cells (Fig. 2-14). Consistently, I observed that AMPK was also 
activated by hypoxia, as indicated by the presence of phosphorylated ACC (Ser79), which 
was prevented by exogenous pyruvate (Fig. 2-15). Phosphorylation of ACC was even 
observed under 21% O2 in Hep3B and H9c2 cells, which may be caused by their 
relatively low basal levels of ATP. Under hypoxic conditions the proliferation rates of all 
cell lines were significantly higher in the presence of exogenous pyruvate (Fig. 2-16). 
These data indicate that exogenous pyruvate facilitates the proliferation of both cancer 
and non-cancer cells under hypoxic conditions, likely by maintaining ATP sufficiency. 
 
Cell proliferation rescued by exogenous pyruvate is not mediated through 
suppressing superoxide in hypoxic cells. 
 
Low levels of ROS may contribute to the activation of signaling pathways and the 
promotion of cellular proliferation, but excessive cellular ROS may damage DNA and 
proteins, and induce apoptosis (Le Belle et al., 2011; Leslie et al., 2003; Trachootham et 
al., 2006). It has been reported that acute and severe hypoxia (<1% O2) induces a burst of 
superoxide which mainly results from impaired ETC (Chandel et al., 2000; Giordano, 
2005b). Pyruvate has been studied as a protective anti-oxidant in non-transformed cells 
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(Hinoi et al., 2006; Kim et al., 2008) (Fig. 2-17). To evaluate the contribution of 
exogenous pyruvate as an ROS scavenger to the proliferation of hypoxic cells, I 
measured superoxide levels in 143B, 143B206 and Hep3B cells under hypoxia in the 
presence or absence of exogenous pyruvate. My results demonstrated that prolonged 
hypoxia did not increase the levels of superoxide under our experimental conditions (Fig. 
2-18 and 19). In particular, the cellular superoxide levels in 143B206 cells were hardly 
detectable (Fig. 2-21). In 143B cells, hypoxia significantly decreased superoxide levels, 
and exogenous pyruvate actually increased the generation of superoxide (Fig. 2-19). 
Similarly, in Hep3B cells no obvious effect of hypoxia on superoxide generation was 
observed, and addition of exogenous pyruvate increased superoxide levels (Fig. 2-19). 
These data indicate that the proliferation-promoting effect of exogenous pyruvate on 
hypoxic cells is unlikely linked to its role as an ROS scavenger.  
 
Well-oxygenated cells release pyruvate. 
 
Next I asked whether well-oxygenated cells release pyruvate, which serves as an 
in vivo source of pyruvate exogenous to hypoxic cells. Normal serum contains about 50 
µM pyruvate, which was set as the initial concentration of pyruvate in the culture media. 
I tested 143B, Hep3B and H9c2 cells in media containing 50 µM of pyruvate under either 
normoxic (21% O2) or hypoxic (2% O2) condition, and then measured the concentrations 
of pyruvate in the media after 24 h. I found that when cells were cultured in 21% oxygen, 
the pyruvate levels in the media significantly increased; on the contrary, culturing cells in 
2% oxygen significantly decreased the pyruvate concentrations in media (Fig. 2-20A, B 
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and C), suggesting well-oxygenated cells, either tumor or non-tumor cells, may release 
pyruvate, while hypoxic cells consume pyruvate. To determine whether physiological 
level of exogenous pyruvate is adequate to promote the proliferation of hypoxic cells, I 
investigated the pyruvate dose response of 143B and HeLa cells under hypoxia. Both cell 
lines were cultured under 2% O2 with addition of 0 mM, 50 μM, 200 μM or 1 mM 
pyruvate, and their proliferation rates were measured. As Fig. 2-20D and E show, the 
physiological level of pyruvate (50 μM) was able to significantly promote the 
proliferation of hypoxic 143B and HeLa cells. Furthermore, the pyruvate-deprived 
culture media in which 143B cells were cultured for 48 hours under 21% O2 was 
sufficient to support the proliferation 143B206 cells (Fig. 2-20F). Taken together, these 
data indicate that the pyruvate released by well-oxygenated cells, serving as an in vivo 
source of exogenous pyruvate, support the proliferation of hypoxic cells. 
 
5). Discussion 
 
Anaerobic glycolysis, described as the Pasteur effect, has been established as a 
cellular adaptation to hypoxia and aerobic glycolysis, the Warburg effect, has been 
considered part of the metabolic transformation in cancer cells. In both models, 
endogenous pyruvate from glycolysis is proposed to support the regeneration of oxidized 
NAD+, facilitating ATP production and other NAD+-dependent metabolism. As such, 
LDHA has been explored as a therapeutic target for cancer therapy (Granchi et al., 2011; 
Le et al., 2010). However, in ETC-defective cells, exogenous pyruvate becomes 
absolutely required for cell survival and proliferation. I note that some metabolites of the 
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glycolytic pathway may be directed to other metabolic pathways such as synthesis of 
serine and glycerol phosphates, leading to shortage of pyruvate for NAD+ recovery. (Yin 
et al., 2012a). More importantly, as an electron carrier, NAD+ is not only needed to accept 
electrons from the glycolytic pathways, but can also be reduced in other metabolic 
reactions (Ying, 2008b). For example, NAD+ is reduced to NADH in a variety of 
metabolic pathways such as Krebs cycle, oxidation of fatty acids and amino acids. Under 
conditions of hypoxia, the Krebs cycle is suppressed by HIF-1-mediated upregulation of 
pyruvate dehydrogenase kinase (PDK1) (Kim, J.W., et al., 2006). NADH from limited 
activity of Krebs cycle and other metabolic reactions may be oxidized by residual amount 
of molecular oxygen through ETC, hence the role of exogenous pyruvate may not be 
obvious in relatively mild or transient hypoxia.  However, for cells with severe, chronic 
hypoxia, or defective ETC when oxygen cannot be used, it becomes clear that 
endogenous pyruvate is insufficient to oxidize NADH generated from all metabolic 
processes, leading to a severe NAD+ depletion, which may eventually inhibit the 
glycolysis and ATP production (Yin, C, et al., 2016). Besides the role in ATP production, 
NAD+ also serves as the substrate of sirtuins and poly(ADP-ribose) polymerases (PARP), 
two important enzymes for cellular signaling pathways and DNA damage repair 
(Chiarugi et al., 2012). Therefore, utilizing exogenous pyruvate to maintain the sufficient 
level of NAD+ is likely to be the most important adaptive strategy for cells under severe 
and chronic hypoxic conditions. 
 
Although exogenous pyruvate may join the intracellular pyruvate pool and 
participate in some important biosynthetic pathways, the biosynthetic role of pyruvate is 
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unlikely the rate-limiting parameter in the oxygen-independent cell proliferation. 
Proliferating cells normally have increased demand for the synthesis of serine, glycine, 
aspartate, NADPH and lipids. Pyruvate, through anaplerotic reactions, may contribute 
carbon to these synthetic activities. Accordingly, it has been reported that PC is a critical 
enzyme for some type of cancers, such as non-small cell lung cancer (Sellers et al., 
2015). However, I observed that substituting pyruvate with pyruvate-derived metabolites 
or precursors (acetyl-CoA, α-KG, succinate and alanine) failed to rescue the proliferation 
of 143B206 cells, and the knockdown of enzymes (PC, PDHA1 and CS) catalyzing 
pyruvate-dependent biosynthesis does not impair pyruvate-mediated rescue of 143B206 
cells. It has been known that tumor cells undergo a dramatic change in cellular 
metabolism. The Warburg effect and increased glutaminolysis are two of the most 
noticeable metabolic alterations (Heiden et al., 2009; Wise and Thompson, 2010). 
Through glutaminolysis driven by nitrogen anabolism, glutamine may provide α-KG to 
replenish the Krebs cycle (Meng et al., 2010). Therefore, the carbon flux from 
glutaminolysis may provide an alternative carbon source to support the proliferative 
biosynthesis of biomembrane lipids, aspartate and other amino acids (Hensley et al., 
2013; Meng et al., 2010). In addition, cells defective in oxygen utilization generally 
proliferate slower than the parental cells, which may reduce the demand of carbon source 
for biosynthesis and make it not a rate limiting parameter. These may provide an 
explanation for why exogenous pyruvate is dispensable for proliferative biosynthesis in 
cells defective for oxygen utilization.  
 
The interesting observation that OAA and aspartate partially rescue the 
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proliferation of 143B206 cells to a certain extent also supports the importance of NAD+ 
homeostasis. During the preparation of this thesis, I noticed OAA/Asp-mediated rescue 
of ETC-defective cells in a recent report where the biosynthesis of Asp was proposed to 
be the critical role of pyruvate-mediated rescue of ETC-defective cells (Birsoy et al., 
2015; Sullivan et al., 2015). In my experimental setting, knockdown of PC did not block 
143B206 proliferation rescued by exogenous pyruvate, indicating the pyruvate to OAA 
pathway is not critical for this rescue. Alternatively, OAA, as a keto acid, may similarly 
act as an electron acceptor in the reaction catalyzed by malate dehydrogenase (MDH1). 
Accordingly, it is possible that Asp may rescue 143B206 proliferation by being 
catabolized to OAA, a reaction catalyzed by the cytosolic aspartate aminotransferase 
(GOT1). Consistent with this explanation, inhibiting citrate synthesis by CS knockdown 
thus conserving OAA relieves NADH accumulation and facilitates NAD+ regeneration. 
While theoretically, most keto-acids may serve as electron acceptors to regenerate NAD+, 
I note that pyruvate shows significantly better rescuing effects than OAA. The underlying 
biochemical mechanisms remain unknown, but a plausible explanation is the 
thermodynamic and enzymatic difference among these reactions. 
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Figure 2-1. Stoichiometric analysis of homeostasis of NAD+ and pyruvate in 
glycolysis. 
143B206 cells exclusively generate ATP through glycolysis. In glycolysis, one molecule 
of glucose is converted into two molecules of pyruvate, with two molecules of ATP 
generated and two molecules of NAD+ converted to two NADH. Theoretically, both 
pyruvate molecules need to be reduced to lactate in order to maintain NAD+ homeostasis, 
which will exclude pyruvate or any other glycolytic metabolites from other metabolic 
processes.   
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Figure 2-2. Dose response of exogenous pyruvate on 143B206 cell proliferation. 
143B206 cells were seeded in 96-well microplates and cultured overnight, then the media 
with indicated concentrations of pyruvate were used to culture cells for additional 48 h. 
Cell numbers were measured using CyQUANT assay. The relative cell numbers were 
normalized with the initial number of plated cells. Error bars indicate SD of ≥ 5 replicates. 
** p< 0.01. 
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Figure 2-3. Exogenous pyruvate is required for proliferation of 143B206 cells. 
143B206 and the parental 143B cells were cultured in the presence or absence of 1 mM 
pyruvate for indicated time. Cell numbers were measured and normalized with the initial 
number of plated cells under normoxia. Cell numbers were normalized with the initial 
number of seeded cells. Error bars indicate SD of triplicates. ** p<0.01. 
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Figure 2-4. Withdraw of exogenous pyruvate induces proliferation arrest of 
143B206 cells. 
Morphology of 143B and 143B206 cells cultured in the presence or absence of 1 mM 
pyruvate for 48 hours were observed with Zeiss Axioplan microscope at 400× 
magnification.  
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Figure 2-5. Exogenous pyruvate enhances lactate yield in 143B206 cells. 
The average extracellular acidification rates (ECAR) were analyzed with Seahorse 
analyzer in 143B and 143B206 cells. 143B and 143B206 cells were plated at 2×104 and 
3×104 cells/well, respectively, in Seahorse plates 18 h prior to the assays. The assay 
media were unbuffered XF assay medium (pH7.4) supplemented with 25 mM glucose, 
and 1 mM or 0 mM pyruvate. Upon completion of assays, cells were treated with trypsin 
and counted for normalization. ECAR values were normalized to mpH/104 cells. Error 
bars indicate SD from 4 replicates. ** p< 0.01. 
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Figure 2-6. Oxygen consumption in 143B and 143B206 cells. 
Oxygen consumption rate (OCR) of 143B and 143B206 cells was measured with 
Seahorse metabolic analyzer. Mitochondrial respiration inhibitors a. 1 μM oligomycin, b. 
300 nM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone and c. 100 nM 
antimycin and retenone were used to test the ETC function shown as test groups. Control 
groups were 143B and 143B206 cells without injections of mitochondrial respiration 
inhibitors. 143B cells showed typical OCR profiles similar to other cancer cells, while 
OCR in 143B206 cells was close to 0 pMoles/min, which was not affected by the 
presence of exogenous pyruvate or the mitochondrial respiration inhibitors, confirming 
143B206 cells have no ETC consumption of oxygen. Trace amount, basal level oxygen 
consumption may be due to non-ETC redox. Error bars indicate SD of ≥ 5 replicates. 
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Figure 2-7. Exogenous pyruvate increases NAD+ level and NAD+/NADH ratio. 
A. 143B and 43B206 cells were cultured under indicated conditions for 24 hours, and 
NAD+ concentration in the lysates of 143B and 143B206 cells was measured and used to 
calculate the total amount of NAD+ in both cell lines (per 106 cells). B. and C. 
NAD+/NADH ratio in 143B and 143B206 cells was also calculated and presented. Error 
bars indicate SD of triplicates. **p<0.01. 
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Figure 2-8. Lactate dehydrogenase activity is required for exogenous pyruvate-
mediated proliferation of 143B206 cells. 
143B206 cells were cultured in media with 1 mM of pyruvate and uridine. The 
knockdown efficiency of lactate dehydrogenase A (LDHA) with LDHA siRNA was 
analyzed with immunoblotting and shown in A. The effects of LDHA-knockdown on 
ECAR in the presence of 1 mM pyruvate were shown in B. The effects of LDHA-
knockdown on 143B206 proliferation in the presence of 1 mM pyruvate were shown in C. 
Cell numbers were normalized to the initial number of seeded cells. Error bars indicate 
SD of triplicates. ** p<0.01. 
  
69 
 
 
 
Figure 2-9. Exogenous pyruvate relieves ATP depletion stress in 143B206 cells. 
143B206 and 143B cells were cultured with indicated conditions for 24 h. ATP levels 
were measured (A). Phosphorylated ACC, as indicator of AMPK activation, and total 
ACC in whole cell lysates were analyzed with immunoblotting analysis (B). α-tubulin 
was used as loading control. Representative result from triplicates is shown.   
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Figure 2-10. Effects of pyruvate-derived metabolites on 143B206 cell proliferation in 
the absence of pyruvate.  
A. 0.5 mM ethyl-acetoacetate, B. 1 mM alanine, C. 1 mM dimethyl-α-KG, D. 1 mM 
dimethyl-succinate, E. 1 mM diethyl-OAA and F. 1 mM aspartate were used to replace 
exogenous pyruvate to rescue 143B206 cells, and cell number was measured with cell 
proliferation assay kit every day. Representative proliferation curves are shown. Cell 
numbers were normalized with the initial number of seeded cells. Error bars indicate SD 
of triplicates. ** p<0.01. 
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Figure 2-11. Knockdown of pyruvate carboxylase does not impair the proliferation 
of 143B206 cells. 
Pyruvate carboxylase (PC) was knocked down in 143B206 cells with siRNA. qRT-PCR 
and immunoblotting were employed to confirm the knockdown efficiency (Left). 
Proliferation curves of the control and knockdown 143B206 cells in the presence of 
exogenous pyruvate were measured (Right). For qRT-PCR, error bars indicate 95% 
confidence interval of triplicates. For proliferation curves, error bars indicate SD of ≥ 5 
replicates. ** p<0.01. 
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Figure 2-12. Knockdown of pyruvate dehydrogenase (lipoamide) alpha 1 does not 
impair the proliferation of 143B206 cells. 
The critical subunit of pyruvate dehydrogenase complex (PDC), PDHA1, was knocked 
down in 143B206 cells with siRNA. Immunoblotting and qRT-PCR were employed to 
confirm the knockdown efficiency. Proliferation curves of the control and knockdown 
143B206 cells in the presence of exogenous pyruvate were measured. For qRT-PCR, 
error bars indicate 95% confidence interval of triplicates. For proliferation curves, error 
bars indicate SD of ≥ 5 replicates. ** p<0.01. 
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Figure 2-13. Knockdown of citrate synthase does not impair the proliferation of 
143B206 cells. 
Citrate synthase (CS) was knocked down in 143B206 cells with siRNA. Immunoblotting 
and qRT-PCR was employed to confirm the knockdown efficiency. Proliferation curves 
of the control and knockdown 143B206 cells in the presence of exogenous pyruvate were 
measured. For qRT-PCR, error bars indicate 95% confidence interval of triplicates. For 
proliferation curves, error bars indicate SD of ≥ 5 replicates. ** p<0.01. 
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Figure 2-14. Exogenous pyruvate increases ATP levels in different hypoxic cell lines. 
A-D. 143B, HeLa, Hep3B and H9c2 cells were cultured with indicated conditions for 24 
h. Cell lysates were collected and ATP levels were measured. Error bars indicate SD of ≥ 
5 replicates. * p<0.05. ** p<0.01. 
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Figure 2-15. Exogenous pyruvate relieves ATP depletion stress in difference cell 
lines. 
A-D. 143B, HeLa, Hep3B and H9c2 cells were cultured with indicated conditions for 24 
h. Phosphorylated ACC and total ACC in whole cell lysates were analyzed with 
immunoblotting analysis. α-tubulin was used as loading control. Representative results 
from triplicates are shown.   
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Figure 2-16. Exogenous pyruvate sustains the proliferation of hypoxic cells. 
143B, HeLa, Hep3B and H9c2 cells were cultured in media supplemented with 0 mM or 
1 mM pyruvate under 2% oxygen for indicated time. The cell numbers were analyzed 
with CyQUANT assays. Cell numbers were normalized with the initial numbers of 
seeded cells. Representative proliferation curves are shown. Error bars indicate SD of ≥ 5 
replicates. ** p< 0.01.   
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Figure 2-17. The potential protective role of pyruvate in hypoxia-induced oxidative 
stress. 
Reactive oxygen species (ROS) was reported to be induced by NADPH oxidases and 
mitochondria electron transfer chain under acute hypoxic conditions. With accumulation 
of excessive ROS, oxidative stress may be induced and causes deteriorating damage. As 
an α-keto acid, pyruvate can accept electrons from ROS and be converted to acetate and 
carbon dioxide, thus relieving oxidative stress and protecting hypoxic cells.  
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Figure 2-18. Exogenous pyruvate-mediated rescue of 143B206 cells is not depending 
on suppression of superoxide. 
143B206 cells were cultured with 21% or 2% oxygen in the presence or absence of 1 mM 
pyruvate. After 24 h, superoxide levels were examined with superoxide detection assay, 
and the signals were observed under confocal microscopy. Superoxide-positive pixels per 
cell were quantified and shown. Error bars indicate SD. Bars represent 100 µm. ** 
p<0.01. a.u., arbitrary units.   
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Figure 2-19. Exogenous pyruvate does not protect hypoxic cells through decreasing 
superoxide generation. 
143B and Hep3B cells were cultured with 21% or 2% oxygen in the presence or absence 
of 1 mM pyruvate. After 24 h, superoxide levels were examined with superoxide 
detection assay, and the signals were observed under confocal microscopy. Superoxide-
positive pixels per cell were quantified and shown. Error bars indicate SD. Bars represent 
100 µm. ** p<0.01. a.u., arbitrary units.  
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Figure 2-20. Well-oxygenated cells release pyruvate and hypoxic cells consume 
pyruvate. 
A. 143B, B. Hep3B, and C. H9c2 cells were seeded in pyruvate-free DMEM 
supplemented with 10% dialyzed FBS and 50 µM pyruvate and cultured in 21% or 2% 
oxygen. After 24 h, pyruvate concentrations in culture media were determined. Control 
groups represented the initial concentration of pyruvate. Error bars indicate SD of 
triplicates. D and E. 143B and HeLa cells were cultured under 2% O2 with addition of 0, 
0.05, 0.2 or 1 mM pyruvate for 3 days. Cell proliferation rate was measured using 
CyQUANT assay. F. 143B cells were cultured in pyruvate-deprived medium under 21% 
O2 for 48 hours. The medium was then collected to culture 143B206 cells. The 
proliferation rate of 143B206 cells in the condition medium was measured. The relative 
cell numbers were normalized with the initial number of plated cells. Error bars indicate 
SD of ≥ 5 replicates. * p<0.05. **p<0.01. 
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Chapter 3: Exogenous pyruvate facilitates hypoxic cell adaptation by regulating 
autophagy and apoptosis 
 
1) Abstract 
Tumor cells require persistent supply of ATP and building blocks and delicately 
balanced redox status to satisfy the pressing demands for rapid proliferation. Even though 
tumor cells transform themselves to rely on enhanced uptake of glucose and glycolysis to 
support energy generation and biomass synthesis and avoid the dependence on molecular 
oxygen in normal tissue cells, low level of oxygen is still required for mitochondria 
oxidative phosphorylation to generate ATP and recycle NAD+ in tumor cells and oxygen 
insufficiency causes deleterious effects including proliferation arrest and apoptosis 
through regulation of various signaling pathways. In Chapter 2 I have demonstrated 
exogenous pyruvate facilitates tumor cell adaptation to hypoxia through supporting 
NAD+ recycling and energy generation. However, whether and how exogenous pyruvate 
is involved in the regulation of cell survival through autophagy and apoptosis is seldom 
studied. In this chapter, I first explored the role of hypoxic exposure and exogenous 
pyruvate in ATP status through AMPK and mTOR signaling pathway. Next I 
investigated how acute and chronic hypoxia affect the induction of autophagy and 
apoptosis and the potential role of exogenous pyruvate in the regulation of cell survival. 
In summary, my data indicate that hypoxia induces ATP depletion stress and induces 
autophagy, while chronic hypoxia initiates apoptosis. Exogenous pyruvate inhibits the 
induction of apoptosis, perhaps through upregulation of autophagy, to facilitate the cell 
survival. 
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2) Introduction 
Hypoxia is always existing in the majority of solid tumor tissues due to the 
defective development of vascularization and rapid consumption of oxygen (Wilson and 
Hay, 2011). Hypoxia also occurs in normal tissues because of ischemia caused by blood 
clots, which is usually related to cardiovascular diseases and ischemic stroke (Giordano, 
2005b). To adapt to the stressful hypoxic conditions, hypoxic cells mainly utilize the 
enhanced glycolysis and lactate fermentation to generate ATP and building blocks 
instead of mitochondria oxidative phosphorylation and TCA cycle and alleviate the 
dependence on oxygen. However, tumor cells still maintain the basic need for molecular 
oxygen and oxygen insufficiency decreases ATP generation, inhibits cell growth and 
induces cell death.  
Two well-studied signaling pathways to regulate ATP status are AMP-activated 
protein kinase (AMPK) pathway and mechanistic target of rapamycin (mTOR) pathway 
(Gleason et al., 2007; Xu et al., 2012; Zhang et al., 2009). Under condition of nutrient 
insufficiency including molecular oxygen, glucose and amino acids, ATP generation was 
impaired and AMP/ATP ratio increases correspondently. The increased AMP/ATP ratio 
induces the phosphorylation and activation of AMPK through the upstream regulator 
LKB1 (Shackelford and Shaw, 2009; Woods et al., 2003). AMPK pathway is a master 
regulator of energy status. Activated AMPK inhibits the synthesis of proteins and lipids 
through phosphorylation and inhibition of mTOR and acetyl-CoA carboxylase (ACC) to 
reserve energy (Winder and Hardie, 1996). AMPK also phosphorylates ULK1 to induce 
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autophagy and recycle nutrients (Egan et al., 2011). AMPK is also reported to 
phosphorylate 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which 
plays a role in energy metabolism and apoptosis (Domenech et al., 2015). mTOR 
pathway is another critical regulator of ATP generation. Active mTOR induces synthesis 
of protein and other macromolecules through phosphorylation of p70S6K and 4E-BP-1 
(Hara et al., 1997; Nojima et al., 2003). mTOR also inhibits the initiation of autophagy 
through ULK1 and ATG5 (Jung et al., 2009). mTOR participates in regulation of energy 
metabolism through upregulating HIF1 as well (Miyasaka et al., 2015). However, mTOR 
upstream regulators including AMPK and TSC1/2 induce the inhibition of mTOR under 
nutrient-insufficient conditions (Inoki et al., 2005; Lee et al., 2007). Therefore, AMPK 
and mTOR antagonize with each other to facilitate cellular adaptation to various ATP 
status, particularly through autophagy and apoptosis. 
Hypoxia has been reported to induce ATP-depleted stress, thus inducing both 
autophagy and apoptosis, but the effects of exogenous pyruvate in regulation of hypoxia-
induced stress, autophagy and apoptosis are not fully appreciated. In this chapter, my 
experiment results show that hypoxia activates AMPK pathway and inhibits mTOR 
pathway, and exogenous pyruvate relieves the hypoxia-induced ATP depletion stress. My 
data also indicate that hypoxia induces autophagy while apoptosis is only induced in 
chronic hypoxia. Finally, I demonstrate that exogenous pyruvate enhances autophagy and 
inhibits apoptosis under chronic hypoxia. Taken together, my findings elucidate a 
potential model that exogenous pyruvate facilitates cell survival under chronic hypoxia 
through activation of autophagy and inhibition of apoptosis. 
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3) Materials and methods 
Cell culture 
 
143B and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 25 mM glucose, 1 mM pyruvate and 4 mM glutamine supplemented 
with 10% fetal bovine serum (FBS). Both cells were cultured in humidified 5% CO2/95% 
air atmosphere at 37 °C. For pyruvate-deprivation study, cells were cultured in pyruvate-
free DMEM with 25 mM glucose, 4 mM glutamine and 10% dialyzed FBS. Experiments 
performed under hypoxic conditions were carried out in the hypoxic chamber Invivo2 300 
(Ruskinn Technology, Sanford, ME) equipped with a programmable controller of 
humidity, temperature and premixed gas (1% O2, 5% CO2, balanced with N2). HeLa cells 
were purchased from ATCC (Chicago, IL). 143B cells were kind gifts from Dr. M. King 
(Thomas Jefferson University, Philadelphia, PA). 
 
Immunoblotting  
 
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% 
Sodium deoxycholate, 0.1% SDS and 1% NP-40), homogenized and centrifuged at 
14,000 rpm for 15 min. The supernatant was collected as whole cell lysates. Protein 
concentrations in the lysates were measured with Bio-Rad Protein Assay Dye Reagent 
Concentrate (BIO-RAD, Hercules, CA). 30 μg of proteins were separated by 8% SDS-
PAGE, transferred to PVDF membrane (BIO-RAD), and probed with specific primary 
antibodies including rabbit anti- Phosphorylated ACC (Ser79) (Catalog # 3661S, 1:1000, 
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Cell Signaling), rabbit anti-ACC (Ser51) (Catalog # 3676S, 1:1000, Cell Signaling), 
rabbit anti- phosphorylated mTOR (Ser2448) (Catalog # 2971S, 1:1000, Cell Signaling), 
rabbit anti-mTOR (Catalog # 2972S, 1:1000, Cell Signaling), rabbit anti-phsosphorylated 
4E-BP1 (Thr37/46) (Catalog # 2855, 1:1000, Cell Signaling), rabbit anti- LC3B (Catalog 
# 3868S, 1:1000, Cell Signaling), rabbit anti- cleaved PARP (Catalog # 5625, 1:1000, 
Cell Signaling), and mouse anti-α-tubulin (Catalog # T9026, 1:5000, Sigma). The 
primary antibodies were detected with appropriate secondary antibody horseradish 
peroxidase-conjugated goat anti-mouse (catalog #A4416, 1:10,000, Sigma) or goat anti-
rabbit (catalog #A6154, 1:10,000, Sigma) and developed with SuperSignal® West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific). 
 
Observation of the LC3-GFP autophagosome formation  
 
Plasmid pEGFP-LC3 was transfected into 143B cells with LipofectamineTM 2000 
Transfection Reagent (Invitrogen) following the manufacturer’s protocol. Briefly, cells 
were seeded into a 60-mm culture dish and were allowed to achieve 95% confluence. 2 
μg plasmids and 6 μL Lipofectamine 2000 Transfection Reagent were incubated in 0.5 
mL Gibco Opti-MEM® I Reduced-Serum Medium (Thermo Fisher Scientific, Waltham, 
MA) for 5 min, respectively, and then mixed and incubated for 20 min. Cells were 
transfected with the mixed medium. 6 h after transfection, 143B cells were seeded into 8-
chamber culture slide (Falcon) for treatment of indicated conditions for 24 hours. Then 
cells were fixed in 4% paraformaldehyde for 10 min and then washed with phosphate 
buffered saline (PBS) twice.  pEGFP-LC3 transfectants were observed with Olympus 
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FV1000 inverted confocal microscope at 400× magnification and photographed with 
FV10-ASW (Olympus, Shinjuku, Tokyo, Japan).  
 
4) Results 
 
Hypoxia activates AMPK signaling pathway and inhibits mTOR signaling pathway 
 
 AMPK pathway has been well characterized as the master energy regulator which 
inhibits energy-consuming processes such as fatty acid synthesis and protein synthesis, 
and upregulates energy generating pathways to increase ATP levels (Inoki et al., 2012; 
Mihaylova and Shaw, 2011a). Particularly, activated AMPK by low ATP levels 
phosphorylates the rate-limiting enzyme in fatty acid synthesis acetyl-CoA carboxylase 
(ACC) at serine 79, which inhibits the activity of ACC, thus inhibiting the synthesis of 
fatty acids (Winder and Hardie, 1996). Therefore, phosphorylation of ACC has been 
widely used as an indicator of ATP status. mTOR pathway is activated under the 
condition with sufficient nutrients, which induces synthesis of proteins and many other 
macromolecules, enhances cellular metabolism and promotes cell proliferation (Yecies 
and Manning, 2011). When nutrients are insufficient, mTOR pathway is inhibited through 
upstream regulators including TSC1/2 and AMPK, and biosynthesis and cell growth are 
inhibited (Inoki et al., 2002). To test the effect of different time of hypoxia on these two 
signaling pathways, 143B and HeLa cell samples were collected after up to 24 hours and 
up to 16 hours respectively before massive cell death under hypoxia (1% O2) was 
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observed. For 143B cells, ACC phosphorylation was increased as soon as 4 hours after 
hypoxic treatment without changing the protein level of total ACC, and phosphorylation 
of ACC was further enhanced and peaked after 16 hours with hypoxic treatment time 
increasing. Interestingly, after 24 hours of hypoxic treatment phosphorylation of ACC 
decreased dramatically compared to 16 hours of hypoxic treatment. But the protein level 
of phosphorylated ACC was still increased compared to that before hypoxic treatment, 
suggesting hypoxia induces ATP depletion stress. Consistent to previous reports, mTOR 
pathway was inhibited constantly by hypoxia in 143B cells (Fig. 3-1). In HeLa cells, 
phosphorylation of ACC was also induced by hypoxia but the relative level was low 
compared to 143B cells until after 16 hours of hypoxic treatment. mTOR phosphorylation 
was inhibited by hypoxia as well (Fig. 3-1). Therefore, hypoxia activates AMPK pathway 
and inhibits mTOR pathway, confirming that hypoxia induces ATP depletion stress. 
 
Exogenous pyruvate alleviates AMPK activation and relieves mTOR inhibition in 
hypoxic cells 
 
Next I examined the effect of exogenous pyruvate on the regulation of AMPK and 
mTOR pathway. 143B cells and HeLa cells were cultured under hypoxia for 24 hours and 
16 hours respectively, and then cell samples were collected for immunoblotting. In both 
143B and HeLa cells, phosphorylation of ACC (Ser79) was induced in hypoxia, which is 
inhibited with the addition of exogenous pyruvate, suggesting exogenous pyruvate 
relieves the ATP depletion stress induced by hypoxia (Fig. 3-2 and 3-3). It was also 
88 
 
observed that hypoxia decreased the phosphorylation of mTOR (Ser2448) and its 
substrate 4E-BP1 (Thr37/46), suggesting that hypoxia inhibits the mTOR pathway. As 
expected, the addition of exogenous pyruvate promoted the phosphorylation of mTOR 
and 4E-BP1, indicating exogenous pyruvate facilitates the activation of mTOR pathway 
under hypoxia (Fig. 3-2 and 3-3). Therefore, exogenous pyruvate relieves ATP depletion 
stress as indicated by inhibited AMPK pathway and activated mTOR pathway. 
 
Autophagy is induced by hypoxia and apoptosis is induced by chronic hypoxia 
ATP is important to support cellular activities. Under hypoxic conditions energy 
generation was inhibited because of inhibited oxidative phosphorylation and autophagy is 
induced to facilitate cellular adaption to the stressful condition (Bellot et al., 2009). When 
energy insufficiency induced by hypoxia persistently exists, cells suffer from inevitable 
damages through apoptosis (Shimizu et al., 1996). To investigate the effect of different 
duration of hypoxia on activation of autophagy and apoptosis, I exploited 
immunoblotting to test the conversion of microtubule-associated proteins 1A/1B light 
chain 3B (LC3B) and cleavage of poly ADP ribose polymerase (PARP). During 
autophagy, the cytosolic form of LC3B I is conjugated with phosphatidylethanolamine to 
form LC3B II and recruited to autophagosomes (Kouroku et al., 2007). Therefore, the 
conversion from LC3B I to LC3B II is a reliable and characteristic marker of autophagy. 
PARP is responsible for DNA repair and it is cleaved and inactivated by caspases when 
apoptosis is activated (Chaitanya et al., 2010). Therefore, cleavage of PARP is a well-
studied apoptosis marker.  143B and HeLa cells were cultured under hypoxia for 
indicated time with or without exogenous pyruvate, and then the cell samples were 
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collected for immunoblotting to test LC3B conversion and cleavage of PARP. As the data 
show, hypoxia persistently induces the conversion of LC3B starting from as soon as 4 
hours, while cleavage of PARP was not induced until after chronic hypoxia treatment 
(after 24 hours in 143B cells and after 16 hours in HeLa cells) (Fig. 3-4), indicating 
hypoxia induces autophagy while chronic hypoxia induces apoptosis. 
 
Exogenous pyruvate enhances initiation of autophagy under chronic hypoxia 
Exogenous pyruvate has been demonstrated to relieve ATP depletion stress under 
hypoxia. Therefore, exogenous pyruvate may play a role in the regulation of autophagy to 
facilitate cellular adaption. To test the idea, 143B and HeLa cells were cultured under 
indicated conditions for 24 hours and 16 hours respectively, and the cell samples were 
collected for immunoblotting to test LC3B conversion. As the data show, LC3B II 
protein level was increased by hypoxia, which was further induced when exogenous 
pyruvate was supplemented (Fig. 3-5). Besides the conversion of LC3B, the formation of 
autophagosomes is another widely used indicator of autophagy. Then I exploited 
immunofluorescence to observe the formation of autophagosomes in 143B cells. After 
transfection with pEGFP-LC3 vector 143B cells were cultured under indicated conditions 
and LC3 puncta were observed. Consistent with LC3B conversion, hypoxia induced 
formation of LC3 puncta, and exogenous pyruvate further increased the number of LC3 
puncta (Fig. 3-6). Taken together, exogenous pyruvate enhances hypoxia-activated 
autophagy to facilitate cell adaption. 
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Exogenous pyruvate inhibits chronic hypoxia-induced apoptosis 
Finally, the effect of exogenous pyruvate on the regulation of apoptosis was 
explored in 143B and HeLa cells. 143B and Hela cells were treated with chronic hypoxia 
(24 hours for 143B cells and 16 hours for HeLa cells) with or without exogenous 
pyruvate, and cell samples were collected to test cleavage of PARP with immunoblotting. 
Cleavage of PARP was observed to be induced by hypoxia which is consistent to the 
previous studies, while the addition of exogenous pyruvate dramatically decreased the 
protein level of cleaved PARP (Fig. 3-7), suggesting exogenous pyruvate inhibits chronic 
hypoxia-induced apoptosis. 
 
5). Discussion 
 Autophagy and apoptosis are two crucial adaptive mechanisms to determine cell 
fate under stressful conditions. Autophagy facilitates cell adaptation through recycling 
amino acids and nutrients from damaged proteins and organelles to maintain energy and 
nutrient homeostasis, whereas apoptosis causes degradation of macromolecules and 
finally induces cell death. Autophagy and apoptosis are considered to be activated by 
similar stressors with different severity, and compete with each other to determine cell 
survival or death (Amaravadi et al., 2007; Boya et al., 2005; Marino et al., 2014; 
Rzymski et al., 2010). Under hypoxic conditions, oxygen insufficiency impairs 
mitochondrial oxidative phosphorylation and decreases ATP levels. ATP depletion 
activates AMPK pathway and inhibits mTOR pathway, which in turn induce initiation of 
autophagy through activating autophagy executors including ULK1 and ATG5 (Kim et 
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al., 2011; Papandreou et al., 2008). Hypoxia also triggers release of cytochrome c and 
activation of apoptosis through intrinsic pathways with the involvement of hypoxia-
inducible factors (HIFs) or not (Carmeliet et al., 1998; Guo et al., 2001; Shimizu et al., 
1996). Interestingly, even in the presence of persistent autophagy, apoptosis occurs in 
cells exposed to chronic hypoxia, implying autophagy alone is not sufficient to prevent 
apoptosis. Recently, I have showed that exogenous pyruvate serves as oxygen surrogate 
to maintain homeostasis of NAD+, a critical coenzyme absolutely needed for glycolysis, 
thus maintaining ATP levels (Yin et al., 2016). My data presented in the thesis show that 
exogenous pyruvate effectively prevents apoptosis and enhances autophagy, further 
indicating a critical role of exogenous pyruvate in promoting cell adaption to chronic 
hypoxia.  
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Figure 3-1. Hypoxia activates AMPK pathway and inhibits mTOR pathway. 
143B and HeLa cells were cultured under hypoxia for up to 24 h and 16 h respectively. 
Total protein samples were collected for Western blotting to determine the protein levels 
of phosphorylated ACC and phosphorylated mTOR. α-tubulin was used as loading 
control. 
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Figure 3-2. Exogenous pyruvate relieves ATP depletion and mTOR inhibition in 
143B cells. 
143B cells were cultured under indicated conditions for 24 h. Total protein samples were 
collected for Western blotting to determine the protein levels of phosphorylated ACC, 
phosphorylated mTOR and phosphorylated 4E-BP1. α-tubulin was used as loading 
control. 
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Figure 3-3. Exogenous pyruvate relieves ATP depletion and mTOR inhibition in 
HeLa cells. 
HeLa cells were cultured under indicated conditions for 16 h. Total protein samples were 
collected for Western blotting to determine the protein levels of phosphorylated ACC, 
phosphorylated mTOR and phosphorylated 4E-BP1 α-tubulin was used as loading control. 
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Figure 3-4. Dynamic analysis of autophagy and apoptosis in 143B and HeLa cells. 
143B and HeLa cells were cultured under hypoxia for up to 24 h and 16 h respectively. 
Total protein samples were collected for Western blotting to determine the protein levels 
of LC3B I, LC3B II (a biomarker of autophagy) and cleaved PARP (a biomarker of 
apoptosis). α-tubulin was used as loading control. 
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Figure 3-5. Exogenous pyruvate enhances hypoxia-activated accumulation of LC3B 
II. 
143B and HeLa cells were cultured under hypoxia for up to 24 h and 16 h respectively. 
Total protein samples were collected for Western blotting to determine the protein levels 
of LC3B I and LC3B II. α-tubulin was used as loading control. 
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Figure 3-6. Exogenous pyruvate enhances autophagosome formation under chronic 
hypoxia. 
143B cells were transfected with a plasmid expressing GFP and then cultured under 
indicated conditions for 24 h. Confocal microscopy was utilized to observe 
autophagosome formation, indicated as punctea. DPAI was exploited to show the nuclei.  
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Figure 3-7. Exogenous pyruvate inhibits apoptosis induced by chronic hypoxia. 
143B and HeLa cells were cultured under hypoxia for up to 24 h and 16 h respectively. 
Total protein samples were collected for Western blotting to determine the protein levels 
of cleaved PARP. α-tubulin was used as loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
Chapter 4: Exogenous pyruvate facilitates hypoxic cell adaptation by maintaining a 
mild ER stress response 
 
1) Abstract 
Molecular oxygen (O2) is the final electron acceptor in mitochondria electron 
transfer chain for ATP generation and NAD+ homeostasis, which are the bases of the 
essential cellular functions and behaviors. However, oxygen availability is always limited 
in solid tumor tissues due to the rapid tumor progression and defective development of 
vascularization. Normal cells within ischemic regions also suffer from hypoxia due to the 
impaired blood transport. In Chapter 2, my studies have demonstrated from the 
perspective of metabolism that exogenous pyruvate serves as the oxygen surrogate to 
maintain ATP synthesis and NAD+ homeostasis, thus promoting the proliferation of 
cancer and non-cancer cells under hypoxic conditions. In Chapter 3, my data also suggest 
that exogenous pyruvate facilitates cell survival under hypoxia through activating 
autophagy and inhibiting apoptosis. However, how cells adapt to the hypoxic 
microenvironment through ER stress response is still not fully appreciated. In this chapter, 
I further explore the important role of exogenous pyruvate in regulation of ER stress 
response. My data show that acute treatment of hypoxia induces the activation of ER 
stress response pathways in 143B and HeLa cells, while chronic hypoxia alleviates the 
activation of these signaling pathways. I observed that the inhibition of ER stress 
response by chronic hypoxia is relieved by exogenous pyruvate. Furthermore, I observe 
that hypoxia, acute or chronic, only induces a relatively mild ER stress response. In a 
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word, exogenous pyruvate maintains the activation of ER stress response under chronic 
hypoxia, which in turn contributes to the rescue of hypoxic cells. 
 
2) Introduction 
Adaptation to hypoxia promotes cancer progression, metastasis and resistance to 
chemotherapy and radiation. To understand the mechanisms by which tumor cells 
respond and adapt to hypoxia is a critical step toward the development of therapy 
specifically targeting hypoxic tumor cells.  In addition to responses mediated by hypoxia-
inducible factors, AMPK and mTOR pathways (Laplante and Sabatini, 2012; Mihaylova 
and Shaw, 2011; Semenza, 2003), endoplasmic reticulum (ER) stress response, as a 
general response to cellular stresses, is also elicited by hypoxia (Koumenis et al., 2007; 
Wouters and Koritzinsky, 2008). ER stress responses are commonly mediated via three 
branches: PERK, ATF6 and IRE1α (Hetz, 2012). At non-stress conditions, the three arms 
of ER stress response are suppressed by a physical interaction with an ER chaperone 
protein, GRP78.  Like other cellular stresses, hypoxia results in an increase of unfolded 
or misfolded proteins in the ER lumen, thus dissociating GRP78 from PERK, ATF6 and 
IRE1α (Bi et al., 2005; Hetz, 2012; Wouters and Koritzinsky, 2008). Activated PERK 
induces phosphorylation of eIF2α, which globally inhibits protein translation and 
selectively translates ATF4 (Harding et al., 2000). ATF6 released from ER membrane 
translocates to Golgi, where it is cleaved to form the transcriptionally active 50 KD form 
(ATF60-p50) (Haze et al., 1999). Activated IRE1α induces the splicing of XBP1 to 
generate the spliced XBP1 (Yoshida et al., 2001). The three ER stress response branches, 
eIF2α-ATF4 pathway, ATF6 pathway and XBP1 pathway, together facilitate cell 
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adaptation to stresses. Collectively, the three arms of ER stress response reduce the 
generation of misfolded proteins, enhance ER capacity to refold misfolded proteins, or 
facilitate the degradation of terminally misfolded proteins (Baumeister et al., 2005; Lee, 
2001; Luo et al., 2003).  
More recently, ER stress also was reported to promote autophagy and apoptosis 
(Kim et al., 2010; Senft and Ronai, 2015). Autophagy facilitates cell adaptation to 
stressful conditions through recycling amino acids and nutrients from proteins and 
organelles to maintain energy and nutrient homeostasis; and apoptosis causes degradation 
of macromolecules and results in cell death. It has been reported that ER-stress induced 
autophagy and apoptosis could be activated by the same stressors with different severity 
(Amaravadi et al., 2007; Boya et al., 2005; Marino et al., 2014; Rzymski et al., 2010). 
Mechanistically, ER stress-induced translation of ATF4 enhances the expression of 
LC3B, a key executor of autophagy (B'chir et al., 2013; Rouschop et al., 2010). On the 
other hand, ATF4 also induces the transcription of the pro-apoptotic transcription factor 
CHOP (Tabas and Ron, 2011). How hypoxia-induced ER stress coordinates autophagy, 
which represents an adaptive response, and apoptosis, which represents a failure to 
adaptation, remains unclear.       
In chapter 2 I have demonstrated that exogenous pyruvate facilitates cellular 
adaption to hypoxia through supporting NAD+ recycling and ATP generation, but 
whether and how exogenous pyruvate affects ER stress response under hypoxia remains 
to be investigated. In this chapter, I demonstrate that even though acute hypoxia activates 
the three branches of ER stress response, chronic hypoxia inhibits ER stress response, 
which is relieved by exogenous pyruvate. Particularly, hypoxia only induces a relatively 
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mild ER stress. Taken together, my data indicate that utilization of exogenous pyruvate is 
required for ER stress response-mediated tumor cell adaptation to chronic hypoxia. 
 
3) Materials and methods 
Cell culture 
 
143B and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 25 mM glucose, 1 mM pyruvate and 4 mM glutamine supplemented 
with 10% fetal bovine serum (FBS). Both cells were cultured in humidified 5% CO2/95% 
air atmosphere at 37 °C. For pyruvate-deprivation study, cells were cultured in pyruvate-
free DMEM with 25 mM glucose, 4 mM glutamine and 10% dialyzed FBS. Experiments 
performed under hypoxic conditions were carried out in the hypoxic chamber Invivo2 300 
(Ruskinn Technology, Sanford, ME) equipped with a programmable controller of 
humidity, temperature and premixed gas (1% O2, 5% CO2, balanced with N2). HeLa cells 
were purchased from ATCC (Chicago, IL). 143B cells were kind gifts from Dr. M. King 
(Thomas Jefferson University, Philadelphia, PA). 
 
Reverse-transcription PCR for spliced XBP1 
 
 Total RNA was extracted with Qiagen RNeasy kit (Invitrogen). cDNA was 
synthesized using SuperScript II Reverse Transcriptase (Invitrogen) and 20 ng cDNA was 
used as the template to amplify unspliced and spliced XBP1 by standard PCR with actin 
103 
 
as the loading control. The PCR procedure applied was 94 °C for 10 min at Stage 1, and 
95 °C for 30 s, 65 °C for 45 s and 72 °C for 30 s for 35 cycles at Stage 2. Primers used 
are listed as below: 
XBP1 
Forward primer: TTACGAGAGAAAACTCATGGCC 
Reverse primer: GGGTCCAAGTTGTCCAGAATGC 
Actin 
Forward primer: CAAACATGATCTGGGTCATCTTCTC 
Reverse primer: GCTCGTCGTTCGACAACGGCT 
 
Immunoblotting  
 
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% 
Sodium deoxycholate, 0.1% SDS and 1% NP-40), homogenized and centrifuged at 
14,000 rpm for 15 min. The supernatant was collected as whole cell lysates. Protein 
concentrations in the lysates were measured with Bio-Rad Protein Assay Dye Reagent 
Concentrate (BIO-RAD, Hercules, CA). 30 μg of proteins were separated by 8% SDS-
PAGE, transferred to PVDF membrane (BIO-RAD), and probed with specific primary 
antibodies including rabbit anti-GRP78 (Catalog # 3177S, 1:1000, Cell Signaling), rabbit 
anti-phospho-eIF2α (Ser51) (Catalog # 3398S, 1:1000, Cell Signaling), rabbit anti-eIF2α 
(Catalog # 5324S, 1:1000, Cell Signaling), rabbit anti-ATF4 (Catalog # 11815S, 1:1000, 
Cell Signaling), goat anti-STC2 (Catalog # sc-14350, 1:1000, Santa Cruz), mouse anti-α-
ATF6 (Catalog # ab122897, 1:1000, Abcam), rabbit anti- LC3B (Catalog # 3868S, 
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1:1000, Cell Signaling), rabbit anti- cleaved PARP (Catalog # 5625, 1:1000, Cell 
Signaling), and mouse anti-α-tubulin (Catalog # T9026, 1:5000, Sigma). The primary 
antibodies were detected with appropriate secondary antibody (horseradish peroxidase-
conjugated goat anti-mouse (catalog #A4416, 1:10,000, Sigma) or goat anti-rabbit 
(catalog #A6154, 1:10,000) from Sigma) and developed with SuperSignal® West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific). 
 
Luciferase activity assay 
Luciferase reporter vectors UPRE-luc reporter, ERSE-luc reporter, and CHOP-luc 
reproter were co-transfected with pRL-Renilla Luciferase vector into 143B cells with 
LipofectamineTM 2000 Transfection Reagent (Invitrogen) following the manufacturer’s 
protocol. Transfected cells were then treated under indicated conditions for 24 h. The 
luciferase activity was measured with Dual-Luciferase® Reporter Assay System 
(Promega, Madison, Wisconsin) based on the manufacturer’s protocol. 
Data analysis  
 
Data in the figures are presented as mean values ± SD. Student’s t-test and 
multivariate analysis of variance were used for statistical analysis. Differences in all the 
tests were considered as statistically significant at p value < 0.05. 
 
4) Results 
Exogenous pyruvate sustains a persistent ER stress response in cells exposed to 
chronic hypoxia. 
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ER stress response plays a crucial role in cellular adaptation to stressful 
conditions including hypoxia and chemoradiation (Hetz, 2012). Particularly, ER stress 
has been found to induce adaptive autophagy through ATF4-dependent upregulating 
LC3B and ATG5 (Rzymski et al., 2010). To evaluate the importance of exogenous 
pyruvate in the determining cell fate as a result of hypoxia, I first investigated the effects 
of hypoxia on the three branches of ER stress response including the eIF2α-ATF4 
pathway, the ATF6 pathway and the XBP1 pathway. I cultured 143B cells under hypoxia 
in the absence of exogenous pyrvate for indicated duration, and protein samples were 
prepared from the cells to examine the activation of the three branches of ER stress 
response. Interestingly, the phosphorylation of eIF2α was persistent and gradually 
increased after hypoxia exposure, whereas ATF4 protein levels peaked at 4 h after 
hypoxia treatment, then gradually decreased and finally became undetectable after 16 h 
(Fig. 4-1). Activation of ATF6 branch was evaluated by determining the levels of the 
active 50KD fragment of ATF6 (ATF6-p50). The highest protein levels of ATF6-p50 
was observed prior to hypoxic treatment, and exposure to hypoxia gradually decreased 
ATF6-p50 levels, suggesting basal level of ATF6 activation exists in 143B cells, and 
hypoxia inhibits the activation of ATF6 branch (Fig. 4-1). The IRE1 arm of ER stress 
response was evaluated by monitoring XBP1 splicing. I observed a basal level of XBP1 
splicing prior to hypoxic treatment, and 16 h exposure to hypoxia did not affect XBP1 
splicing significantly.  However, after 24 h exposure to hypoxia, XBP1 splicing 
disappeared following the suppression of ATF4 and ATF6 (Fig. 4-1). Therefore, in the 
absence of exogenous pyruvate, acute hypoxia mainly activates ATF4 pathway, whereas 
chronic hypoxia inhibits all three arms of ER stress response in 143B cells, which 
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temporarily correlates with apoptosis. To further delineate the link between exogenous 
pyruvate and cell fate in response to hypoxia, I next asked how presence of exogenous 
pyruvate may affect the ER stress response in cells under chronic hypoxia. I cultured 
143B cells for 24 h in the presence or absence of exogenous pyruvate. Chronic hypoxic 
treatment did not affect the protein level of phosphorylated eIF2α and ATF4 dramatically, 
and decreased ATF6-p50 protein level. I also observed that after 24 h exposure to 
hypoxia, the presence of exogenous pyruvate maintained enhanced levels of eIF2α 
phosphorylation, ATF4 protein levels and ATF6-p50 (Fig. 4-2). Similar to eIF2α-ATF4 
pathway and ATF6 pathway, the presence of exogenous pyruvate resulted in a higher 
level of spliced XBP1 (Fig. 4-3). In HeLa cells cultured in pyruvate-free media, the 
phosphorylation of eIF2α, levels of ATF4 and ATF6-p50 peaked at 8 h after hypoxic 
exposure, but all decreased after 16 h (Fig. 4-4). Similarly, the presence of exogenous 
pyruvate maintained ER stress response at relatively high levels (Fig. 4-5 and 4-6). 
Taken together, these data indicate that exogenous pyruvate is critical to maintain ER 
stress response in cells experiencing chronic hypoxia.  
 
Hypoxia triggers a relatively mild ER stress response. 
 The apoptotic transcription factor CHOP is a marker of ER stress response in the 
apoptotic phase, which is usually induced by cytotoxic ER stress-inducing drugs such as 
tunicamycin (TM) and thapsigargin (TG) (Marciniak et al., 2004; Zinszner et al., 1998). 
It has been reported that under severe ER stress, ATF4 induces the expression of CHOP, 
thus activating apoptosis (Tabas and Ron, 2011). To investigate the severity of ER stress 
induced by hypoxia, I tested the protein levels of CHOP under different duration of 
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hypoxia. 143B cells were cultured under hypoxia without exogenous pyruvate for up to 
24 hours and proteins samples were collected to test the expression of CHOP. 
Tunicamycin treatment under normoxia was set as the positive control. I observed that 
the protein levels of CHOP under hypoxia were hardly detectable compared to positive 
control (Fig. 4-7A). As exogenous pyruvate maintains ER stress response under chronic 
hypoxia, the effect of exogenous pyruvate on CHOP expression was also investigated. 
Interestingly, I observed that exogenous pyruvate did not induce expression of CHOP 
(Fig. 4-7B). Similar results were also observed in HeLa cells (Fig. 4-7C and D). I also 
employed the luciferase assay to determine the effects of hypoxia on activation of ER 
stress response. UPRE-luc reporter, ERSE-luc reporter and CHOP-luc reporter were 
respectively used as the indicator of the three arms of ER stress response including 
IRE1α-XBP1 pathway, ATF6 pathway and ATF4 pathway (Duan et al., 2015). 143B 
cells were transfected with the three luciferase reporters respectively and then treated 
with 21% or 1% O2 in the presence of exogenous pyruvate or not for 24 hours. The 
treatment of tunicamycin was the positive control as mentioned. I found that the 
luciferase activity of the three reporters was dramatically lower than the positive control 
regardless of treatment of hypoxia or exogenous pyruvate (Fig. 4-8A, B and C). These 
results indicate that hypoxia only induces a relatively mild ER stress response.  
  
 5). Discussion 
 ER stress response is an important mechanism by which cells adapt to a variety of 
stress factors which cause disruptive energy generation, misbalanced redox status or 
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accumulation of misfolded proteins (Ron and Walter, 2007). In acute hypoxia, ER stress 
response reduces the load of misfolded proteins to ER lumen through translational 
inhibition mediated by phosphorylation of eIF2α and IRE1α-dependent degradation of 
mRNA (Harding et al., 2000; Hollien and Weissman, 2006; Koumenis et al., 2002). 
When hypoxic conditions continue, the protein folding and processing capacity of ER is 
further enhanced through the transcription factors ATF6, XBP1 and ATF4 (Acosta-
Alvear et al., 2007). For example, hypoxia induces expression of the autophagy effectors 
LC3B and ATG5 through ATF4 to promote autophagy (B'chir et al., 2013; Rouschop et 
al., 2010). CHOP is a marker of ER stress response in the apoptotic phase, which is 
usually induced by cytotoxic ER stress-inducing drugs such as tunicamycin and 
thapsigargin (Marciniak et al., 2004; Zinszner et al., 1998). It also has been reported that 
under severe ER stress, ATF4 induces the expression of the apoptotic transcription factor 
CHOP, thus activating apoptosis (Tabas and Ron, 2011). I found that ER stress response 
is activated by acute hypoxia but inhibited by chronic hypoxia in the absence of 
exogenous pyruvate, but the expression of CHOP was hardly detectable. Consistently, I 
found that hypoxia as low as 1% O2 failed to stimulate the luciferase reporters that are 
represent the severity of ER stress responses, indicating that hypoxia, acute or chronic, 
does not trigger ER stress responses severe enough to active CHOP pathways in tumor 
cells. It remains unclear how chronic hypoxia, in the absence of exogenous pyruvate, 
triggers CHOP-independent apoptosis. I propose that as an active self-adaptation, the 
activation and execution of ER stress responses need the investment of energy and 
building blocks to facilitate protein phosphorylation, protein cleavage and mRNA 
splicing. Without exogenous pyruvate, chronic hypoxia gradually exhausts NAD+, thus 
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inhibiting glycolysis and ATP production. The energy shortage may be a key factor that 
on one hand, impairs an adaptive ER stress response; on the other hand, triggers 
alternative apoptotic pathways. 
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Figure 4-1. Time course of ER stress response in 143B cells under chronic hypoxia. 
ER stress response pathways are inhibited after chronic exposure to hypoxia (1% O2). 
143B cells were cultured under hypoxia for 0 h, 4 h, 8 h, 16 h and 24 h. Total protein 
samples and mRNA samples were collected for Western blotting and reverse 
transcription PCR respectively to determine the protein levels of phosphorylated eIF2α, 
ATF4, ATF6 and the mRNA levels of spliced and unspliced XBP1. α-tubulin and β-actin 
were determined and used as loading control for proteins and mRNAs respectively. 
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Figure 4-2. Exogenous pyruvate sustains the ATF4 and ATF6 pathways in 143B 
cells under chronic hypoxia. 
143B cells were cultured with indicated treatments for 24 h. Total protein samples were 
collected for immunoblotting to determine the protein levels of phosphorylated eIF2α, 
ATF4 and ATF6. α-tubulin was used as loading control. 
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Figure 4-3. Exogenous pyruvate facilitates the XBP1 pathway in 143B cells under 
chronic hypoxia. 
143B cells were cultured with indicated treatments for 24 h. Total mRNA samples were 
collected for reverse transcription PCR to determine the mRNA levels of spliced and 
unspliced XBP1. β-actin was used as loading control. 
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Figure 4-4. Time course of ER stress response in HeLa cells under hypoxia. 
ER stress response pathways are inhibited after chronic exposure to hypoxia (1% O2). 
HeLa cells were cultured under hypoxia for 0 h, 4 h, 8 h, and 16 h. Total protein samples 
and mRNA samples were collected for Western blotting and reverse transcription PCR 
respectively to determine the protein levels of phosphorylated eIF2α, ATF4, ATF6, and 
the mRNA levels of spliced and unspliced XBP1. α-tubulin and β-actin were determined 
and used as loading control of proteins and mRNAs respectively. 
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Figure 4-5. Exogenous pyruvate sustains the ATF4 and ATF6 pathways in HeLa 
cells under chronic hypoxia. 
HeLa cells were cultured with indicated treatments for 16 h. Total protein samples were 
collected for immunoblotting to determine the protein levels of phosphorylated eIF2α, 
ATF4 and ATF6. α-tubulin was used as loading control. 
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Figure 4-6. Exogenous pyruvate facilitates the XBP1 pathway in HeLa cells under 
chronic hypoxia. 
HeLa cells were cultured with indicated treatments for 16 h. Total mRNA samples were 
collected for reverse transcription PCR to determine the mRNA levels of spliced and 
unspliced XBP1. β-actin was used as loading control. 
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Figure 4-7. Hypoxia is insufficient to induce CHOP expression. 
A. and B. 143B cells were cultured with indicated treatments. Total protein samples were 
collected for immunoblotting to determine the protein levels of CHOP. α-tubulin was 
used as loading control. C. and D.  HeLa cells were cultured with indicated treatments. 
Total protein samples were collected for immunoblotting to determine the protein levels 
of CHOP. α-tubulin was used as loading control. 
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Figure 4-8. Hypoxia triggers a relatively mild ER stress response. 
143B cells were transfected with UPRE-luc reporter (A), ERSE-luc reporter (B), and 
CHOP-luc reporter (C) respectively, and treated with indicated conditionsfor 24 hours. 
tunicamycin (2 μM , 21% O2) without exogenous pyruvate was used as a positive control 
of ER stress. 
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Chapter 5: GRP78 is required for the exogenous pyruvate-mediated cell survival 
and proliferation under hypoxia. 
 
1) Abstract 
Hypoxia is a consistent feature in the majority of solid tumor tissues. It has 
extensively studied how tumor cells adapt to the stressful hypoxic microenvironment. In 
the previous chapters, I have demonstrated that exogenous pyruvate plays a critical role 
to facilitate the survival and proliferation of hypoxic tumor cells. To be specific, in the 
chapter 2, I report that exogenous pyruvate facilitates the adaption of tumor cells to 
hypoxic through serving as an oxygen surrogate to support NAD+ recycling and ATP 
production; in the chapter 3, my results demonstrate that exogenous pyruvate enhances 
autophagy and inhibits apoptosis under hypoxia to promote cell survival; and in the 
chapter 4, my data further show that exogenous pyruvate maintains the activation of ER 
stress response under chronic hypoxia. However, whether and how the exogenous 
pyruvate regulates autophagy and apoptosis through ER stress response is unclear. 
GRP78 is a central regulator and major target of ER stress response. Recently, it has also 
been reported that GRP78 plays an important role to promote cancer progression and 
chemoradiation resistance through inhibiting apoptosis. As exogenous pyruvate maintains 
the activation of ER stress response, it is interesting to know whether exogenous pyruvate 
may facilitate the adaption of tumor cells to hypoxia with involvement of GRP78. In this 
chapter, I first show that exogenous pyruvate upregulates the expression of GRP78 in 
hypoxic tumor cells. Then my results demonstrate that knockdown of GRP78 impairs the 
protective role of exogenous pyruvate in hypoxic tumor cells. Taken all together, my data 
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indicate that GRP78 is required for the exogenous pyruvate-mediated cell survival under 
hypoxia.  
 
2) Introduction 
 
GRP78 is a ubiquitously expressed protein chaperone that majorly resides in ER. 
It is both the master regulator and the major downstream target of ER stress response to 
adapt to the stressful conditions. Recently, many findings are reported demonstrating that 
GRP78 has more diverse cellular functions and locations beyond facilitating protein 
folding in ER (Lee, 2007). GRP78 overexpression is also widely revealed in cancer cell 
lines and is associated with tumor progression and metastasis (Lee, 2007; Miao et al., 
2013). More evidence is emerging to indicate that GRP78 is a promising therapeutic 
target for cancer diagnosis and therapy. 
Extensive studies have revealed that GRP78 overexpression in cancer cells 
confers resistance against cancer therapies, including radiation therapy and anti-cancer 
chemical drugs (Koomagi et al., 1999; Lee, 2007). In endoplasmic reticulum, GRP78 acts 
as the ER stress response regulator and executor to facilitate cellular adaptation to ER 
stress and cell survival. As a protein chaperone, GRP78 facilitates protein folding, protein 
quality control and degradation in ER. GRP78 also functions as the pivotal regulator of 
ER stress response by binding and inhibiting PERK, IRE1α and ATF6. When unfolded or 
misfolded proteins accumulate in ER, GRP78 is dissociated to facilitate protein folding 
and ER stress response pathways are consequently activated (Wang et al., 2009). Beyond 
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ER, GRP78 at various cellular locations stimulates cell proliferation and inhibits cell 
death through interaction with diverse effectors. GRP78 was observed in a complex with 
caspase 7 to protect cells from apoptosis triggered by etoposide (Reddy et al., 2003). 
GRP78 was also discovered to be associated with mitochondria to maintain mitochondria 
permeability and protect against ER-stress-induced apoptosis (Shu et al., 2008). 
Furthermore, GRP78 is found to be required for stress-induced autophagy to prevent cell 
death through an unclear mechanism (Li et al., 2008). Therefore, GRP78 has crucial pro-
proliferation and anti-apoptosis functions in tumor cells. 
In Chapter 3 and Chapter 4, my results respectively demonstrate that exogenous 
pyruvate facilitates tumor cell adaptation to hypoxia through enhancing autophagy and 
inhibiting apoptosis, and maintaining the activation of ER stress response. GRP78 is a 
linker between ER stress response and cell survival, but whether GRP78 plays a critical 
role in the exogenous pyruvate-mediated protection in hypoxic tumor cells is unclear. In 
this chapter, I demonstrate that exogenous pyruvate upregulates the expression of GRP78 
in hypoxic tumor cells. Then my data show that knockdown of GRP78 impairs the 
exogenous pyruvate-mediated protection of hypoxic tumor cells. Taken all together, my 
data indicate that GRP78 is critical for the exogenous pyruvate-mediated cell survival 
under hypoxia.  
 
3) Materials and methods 
 
Cell culture 
121 
 
 
143B and HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 25 mM glucose, 1 mM pyruvate and 4 mM glutamine supplemented 
with 10% fetal bovine serum (FBS). Both cells were cultured in humidified 5% CO2/95% 
air atmosphere at 37 °C. For pyruvate-deprivation study, cells were cultured in pyruvate-
free DMEM with 25 mM glucose, 4 mM glutamine and 10% dialyzed FBS. Experiments 
performed under hypoxic conditions were carried out in the hypoxic chamber Invivo2 300 
(Ruskinn Technology, Sanford, ME) equipped with a programmable controller of 
humidity, temperature and premixed gas (1% O2, 5% CO2, balanced with N2). HeLa cells 
were purchased from ATCC (Chicago, IL). 143B cells were kind gifts from Dr. M. King 
(Thomas Jefferson University, Philadelphia, PA). 
 
Quantitative real-time PCR (qRT-PCR)  
 
Total RNA was extracted with Qiagen RNeasy kit (Invitrogen). cDNA was 
synthesized using SuperScript II Reverse Transcriptase (Invitrogen), and then used for 
quantitative analysis with specific TaqMan probes for GRP78 (Hs00607129_gH) and β-
actin (Hs01060665_g1) in StepOnePlus Real-Time PCR System (Applied Biosystems, 
Foster City, CA). Briefly, cDNA was amplified in 20μL reactions containing 1 μL of 
probe and 10 μL of 2× Taqman® Gene Expression Master Mix (Applied Biosystems). The 
procedure applied was 50 °C for 2 min and 95 °C for 10 min at Stage 1, 95 °C for 15 s 
and 60 °C for 1 min for 40 cycles at Stage 2. Data were quantitatively analyzed by the 
software StepOneTM v2.1 (Applied Biosystems) with comparative CT method. β-actin 
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was used as endogenous control. All genes were analyzed in triplicates.  
 
Immunoblotting  
 
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% 
Sodium deoxycholate, 0.1% SDS and 1% NP-40), homogenized and centrifuged at 
14,000 rpm for 15 min. The supernatant was collected as whole cell lysates. Protein 
concentrations in the lysates were measured with Bio-Rad Protein Assay Dye Reagent 
Concentrate (BIO-RAD, Hercules, CA). 30 μg of proteins were separated by 8% SDS-
PAGE, transferred to PVDF membrane (BIO-RAD), and probed with specific primary 
antibodies including rabbit anti-GRP78 (Catalog # 3177S, 1:1000, Cell Signaling), rabbit 
anti-phospho-eIF2α (Ser51) (Catalog # 3398S, 1:1000, Cell Signaling), rabbit anti-eIF2α 
(Catalog # 5324S, 1:1000, Cell Signaling), rabbit anti-ATF4 (Catalog # 11815S, 1:1000, 
Cell Signaling), goat anti-STC2 (Catalog # sc-14350, 1:1000, Santa Cruz), mouse anti-α-
ATF6 (Catalog # ab122897, 1:1000, Abcam), rabbit anti- LC3B (Catalog # 3868S, 
1:1000, Cell Signaling), rabbit anti- cleaved PARP (Catalog # 5625, 1:1000, Cell 
Signaling), and mouse anti-α-tubulin (Catalog # T9026, 1:5000, Sigma). The primary 
antibodies were detected with appropriate secondary antibody (horseradish peroxidase-
conjugated goat anti-mouse (catalog #A4416, 1:10,000, Sigma) or goat anti-rabbit 
(catalog #A6154, 1:10,000) from Sigma) and developed with SuperSignal® West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific). 
 
CRIPSR/Cas9 Genome Engineering  
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Target gene primer was designed by using online CRISPR design tool 
(http://crispr.mit.edu/), and then integrated into pX330 plasmid by following the protocol 
provided by Zhang lab (http://www.genome-engineering.org/crispr) (Cong et al., 2013). 
To create a stable gene knockout cell line, cells were first co-transfected with 800 ng 
pX300 and 200 ng pcDNA3.0 plasmid. Finally, the stable gene knockout cell populations 
were selected by appropriate concentration of g418 (for 143B cell use 1 mg/mL of g418). 
The sequences of oligos for GRP78 knockdown are: 
 5’ – CACCGCGACATAGGACGGCGTGATG - 3’ 
 5’ – AAACCATCACGCCGTCCTATGTCGC - 3’. 
 
Cell proliferation assay  
 
Cell growth rate was determined by CyQUANT® NF Cell Proliferation Assay Kit 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. In brief, cells were 
plated at density of 100-500 cells per well in a 96-well microplate. Cell numbers in wells 
were measured every one or two days. Culture medium was removed gently, 50 μL of 
CyQUANT® NF dye solution (which exhibits strong fluorescence enhancement after 
binding with DNA) was added to the well and then the microplate was covered and 
incubated at 37 °C for 30 minutes. The fluorescence intensity was measured using a 
fluorescence microplate reader with excitation at 485 nm and emission detection at 530 
nm. As DNA content is closely proportional to cell number, the assay is designed to 
produce a linear analytical response from at least 100-20,000 cells per well in a 96-well 
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microplate. The relative cell number was calculated with the initial cell number 
normalized to 1. 
 
Data analysis  
 
Data in the figures are presented as mean values ± SD. Student’s t-test and 
multivariate analysis of variance were used for statistical analysis. Differences in all the 
tests were considered as statistically significant at p value < 0.05. 
 
4) Results 
 
Exogenous pyruvate prevents the inhibition of GRP78 expression by chronic 
hypoxia. 
GRP78 is an ER chaperone which not only controls the ER stress response but 
also participates in protein folding in the ER lumen (Lee, 2005). The binding of GRP78 
to PERK, ATF6 and IRE1α inhibits the activation of the three branches of ER stress 
response (Bertolotti et al., 2000; Shen et al., 2002). GRP78 is transcriptionally regulated 
by ATF4, ATF6 and XBP1 (Baumeister et al., 2005; Luo et al., 2003), forming a negative 
regulatory loop of ER stress response. Therefore, GRP78 plays a critical role in the 
regulation and execution of ER stress response (Fig. 5-1). To investigate the interaction 
between chronic hypoxia and exogenous pyruvate on the expression of GRP78, I cultured 
143B cells under normoxia or hypoxia with or without exogenous pyruvate for 24 h. I 
observed that chronic hypoxia only slightly upregulated the mRNA levels of GRP78, but 
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the presence of exogenous pyruvate in culture media of hypoxic cells dramatically 
increased GRP78 mRNA levels (Fig. 5-2). Consistently, the presence of exogenous 
pyruvate increased the protein levels of GRP78 (Fig. 5-2). In HeLa cells, chronic hypoxia 
slightly decreased the mRNA and protein levels of GRP78, and exogenous pyruvate 
prevented the decrease of GRP78 mRNA and protein (Fig. 5-3).  
 
GRP78 is required for the exogenous pyruvate-mediated cell survival and 
proliferation under hypoxia. 
GRP78 has been reported to be localized on the cell surface and mediates the pro-
survival signal in tumor cells (Zhang et al., 2010). In addition, GRP78 is required for ER 
integrity and autophagy initiation and prevent apoptosis (Li et al., 2008). To address 
whether GRP78 is critical for the exogenous pyruvate-mediated cell adaptation to chronic 
hypoxia, I exploited CRISPR-based gene-editing technique to delete one allele of GRP78 
gene and generated a stable 143B cell line with single copy of GRP78 (Fig. 5-4A). I 
confirmed that GRP78 protein levels were decreased to around half of the control group 
(Fig. 5-4B). Control 143B cells and 143B GRP78 (+/-) cells were cultured in the 
indicated conditions for 48 h and the relative cell numbers were measured. I observed 
that under normoxic condition, there was no significant difference in cell proliferation 
rates between 143B and 143B GRP78(+/-) cell lines.  When cultured in chronic hypoxia 
without exogenous pyruvate, the proliferation rates of 143B were inhibited, but it was 
significantly enhanced by the presence of exogenous pyruvate (Fig. 5-4C).  However, 
exogenous pyruvate failed to effectively rescue the proliferation of 143B GRP78(+/-) 
cells in chronic hypoxia (Fig. 5-4C). To understand if GRP78 is critical in determining 
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the autophagy or apoptosis during chronic hypoxia, I cultured 143B cells under the 
experimental conditions and monitored autophagy and apoptosis. We observed that 
chronic hypoxia induced more severe apoptosis in 143B GRP78 (+/-) cells comparing to 
the control 143B cells, and exogenous pyruvate failed to effectively prevent the apoptosis 
triggered by chronic hypoxia (Fig. 5-5). Taken together, my data indicate that the ER-
stress/GRP78 axis is a critical mediator of the exogenous pyruvate-facilitated cancer cell 
adaptation to chronic hypoxia. 
 
5). Discussion 
In this chapter, I first investigated the effect of hypoxia and exogenous pyruvate 
on GRP78 expression. Consistent to the findings in Chapter 4 that exogenous pyruvate 
relieves the inhibition of ER stress response by chronic hypoxia, I found that exogenous 
pyruvate transcriptionally increases the expression of GRP78 in chronic hypoxia. To 
study the role of GRP78 in cell survival and proliferation, GRP78 was knockdown down 
with CRISPR/Cas9 gene editing technique. The knockdown of GRP78 significantly 
impairs the rescuing effect of exogenous pyruvate for cell proliferation and disrupts the 
protective role of exogenous pyruvate to enhance autophagy and inhibit apoptosis. 
Therefore, GRP78 is required for the exogenous pyruvate-mediated cell survival and 
proliferation under hypoxia. 
 
GRP78 has been extensively investigated as the master regulator of ER stress 
response. The binding of GRP78 to PERK, ATF6 and IRE1α inhibits the activation of the 
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three branches of ER stress response (Bertolotti et al., 2000; Shen et al., 2002). GRP78 is 
also an important downstream target in ER stress response and is regulated by ATF4, 
ATF6 and XBP1 (Baumeister et al., 2005; Luo et al., 2003). Therefore, GRP78 plays a 
critical role in the regulation and execution of ER stress response. Recently it was 
reported that GRP78 was localized on the cell surface to mediate the pro-survival signal 
in tumor cells. GRP78 is also reported to be required for ER integrity and autophagy 
initiation and prevent apoptosis (Lee et al., 2008; Li and Lee, 2006; Misra et al., 2006). 
Therefore, besides regulating ER stress response, GRP78 also plays a key role in the 
facilitation of cell survival. Accordingly, induction of ER chaperone GRP78 upon cell 
stress may represent another important cellular adaptive mechanism. My data indicate 
that exogenous pyruvate prevents the inhibition of GRP78 expression by chronic hypoxia. 
My results also show that GRP78 is required for the exogenous pyruvate-mediated cell 
survival and proliferation under hypoxia, demonstrating that the significance of GRP78 in 
cancer progression. Therefore, targeting GRP78 may block tumor cells’ adaptation to 
chronic hypoxia through exogenous pyruvate and contributes to development of effective 
treatment for cancers. 
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Figure 5-1.  Schematic illustration of the role of GRP78 in ER stress response. 
Under normal condition, GRP78 associates with PERK, ATF6 and IRE1α to suppress ER 
stress response. Under stressful conditions, accumulation of misfolded proteins causes 
dissociation of GRP89 from PERK, ATF6 and IRE1α, activating ER stress response. 
GRP78 is also an important downstream target in ER stress response and is 
transcriptionally regulated by ATF4, ATF6 and XBP1. Therefore, GRP78 plays a critical 
role in the regulation and execution of ER stress response and serves as a chaperone 
facilitating protein misfolding.  
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Figure 5-2. Exogenous pyruvate upregulates GRP78 expression levels under chronic 
hypoxia in 143B cells. 
A. 143B cells were cultured under hypoxia for 24 h. Total mRNA samples were collected 
for qRT-PCR to determine the mRNA levels of GRP78. β-actin was determined as a 
loading control. Error bars indicate 95% confidence interval of triplicates. B. 143B cells 
were cultured under 1% O2 for 24 h. Total protein samples were collected for 
immunoblotting to determine the protein levels of GRP78. α-tubulin was used as a 
loading control. 
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Figure 5-3. Exogenous pyruvate upregulates GRP78 expression levels under chronic 
hypoxia in HeLa cells. 
A. HeLa cells were cultured under hypoxia for 24 h. Total mRNA samples were collected 
for qRT-PCR to determine the mRNA levels of GRP78. β-actin was used as a loading 
control. Error bars indicate 95% confidence interval of triplicates. B. HeLa cells were 
cultured under 1% O2 for 24 h. Total protein samples were collected for immunoblotting 
to determine the protein levels of GRP78. α-tubulin was used as a loading control. 
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Figure 5-4. GRP78 knockdown inhibits exogenous pyruvate-mediated cell 
proliferation under hypoxia. 
A. One of two GRP78 alleles was deleted with CRISPR/Cas9 genome editing. B. The 
knockdown efficiency was validated with immunoblotting. C. The proliferation rates of 
GRP78-knockdown cell line and control cell line were determined under indicated 
conditions with CyQUANT NF cell proliferation assay kit. Fold of cell numbers were 
normalized with the initial numbers of seeded cells. Error bars indicate SD of ≥ 5 
replicates. ** p< 0.01.   
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Figure. 5-5. GRP78 is required for the exogenous pyruvate-facilitated cell survival 
under hypoxia. 
143B cells and GRP78-knockdown 143B cells were cultured under 1% O2 or 21% O2 for 
24 h. Total protein samples were collected for Western blotting to determine the protein 
levels of GRP78, LC3B conversion and PARP cleavage. α-tubulin was used as a loading 
control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
133 
 
Chapter 6: General discussion 
 
1). Summary of major findings 
In Chapter 2, I interrogated the role of exogenous pyruvate in supporting the 
proliferation of cells defective for oxygen utilization, with an emphasis on the metabolic 
relevance to hypoxic cells. I showed that exogenous pyruvate significantly alleviated the 
inhibitory effects of ETC deficiency and hypoxia on both cancer cells (143B206, 143B, 
HeLa and Hep3B) and non-cancer cells (H9c2, rat cardiomyocytes). Whereas pyruvate 
may play a role in anaplerosis and participates in multiple biosynthetic pathways, I 
demonstrate that the rescuing effect of exogenous pyruvate for hypoxic cells is mainly by 
acting as an oxygen surrogate to accept electrons, thus maintaining cellular NAD+ levels 
to ensure the continuation of glycolysis and ATP production. While the biochemical role 
of exogenous pyruvate is basically identical to that of endogenous pyruvate derived from 
intracellular glycolysis, the dependence of exogenous pyruvate for hypoxic cells greatly 
expands our understanding of the interaction between hypoxic and normoxic cells during 
the adaptation processes. 
 
 In chapter 3 to 5, I further evaluated the importance of exogenous pyruvate in 
cancer cell adaptation to chronic hypoxia. My data show that in the absence of exogenous 
pyruvate, chronic hypoxia causes ATP depletion stress and triggers apoptosis regardless 
of the persistent autophagy. However, exogenous pyruvate enhances autophagy and 
inhibits apoptosis, thus facilitating cell adaptation to chronic hypoxia. I also observed that 
hypoxia first activates a mild ER stress response, which gradually diminishes in the 
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absence of exogenous pyruvate, a process correlated with apoptosis. In the presence of 
exogenous pyruvate ER stress response will be persistent, and the enhanced expression of 
LC3B, GRP78 and possibly other pro-survival proteins may contribute to the prevention 
of apoptosis. Taken together, my findings provide evidence that exogenous pyruvate 
plays an indispensable role in supporting cell survival and proliferation in chronic 
hypoxic environment through enhancing autophagy, inhibiting apoptosis and maintaining 
ER stress response.  
 
 2). An integrated view of the role of exogenous pyruvate in cell adaptation to 
hypoxia 
Taken all data reported in this thesis together, I propose an integrated model to 
illustrate the important role of exogenous pyruvate in cellular adaptation to chronic 
hypoxia. My study provides evidence to support that exogenous pyruvate facilitates 
oxygen-independent survival and proliferation of cancer cells under chronic hypoxic 
conditions through supporting NAD+ recycling and ATP production, and maintaining a 
mild ER stress response. As depicted in Figure 6-1, in the absence of exogenous 
pyruvate, chronic hypoxia induces exhaustion of ATP, thus inhibiting adaptive ER stress 
response and inducing apoptosis. In the presence of exogenous pyruvate, ER stress 
response activation is sustained, which enhances expression of LC3B and GRP78, thus 
prommoting autophagy and inhibiting apoptosis. 
 
3). Future directions 
135 
 
Data from cell culture studies clearly indicate that exogenous pyruvate enhances 
cell viability and supports oxygen-independent proliferation of ETC-defective cells. 
Within an in vivo environment, the source of pyruvate exogenous to solid tumor cells is 
an interesting question. I have shown that well-oxygenated cells release pyruvate into 
culture media. It has been well-known that hypoxic tumor cells export lactate and well-
oxygenated tumor cells uptake lactate as substrate for metabolism (Pavlides et al., 2009; 
Whitaker-Menezes et al., 2011). Taking these facts together, I propose that adjacent well-
oxygenated cells, including normal cells, tumor cells or stromal cells, may release 
pyruvate, while hypoxic cells uptake and use the exogenous pyruvate as an oxygen 
surrogate to maintain the intracellular NAD+ levels to survive and proliferate (Fig. 6-2). 
How the secretion of pyruvate by non-hypoxic cells is regulated, and particularly, 
whether hypoxic or cancer cells positively regulate the pyruvate secretion from adjacent, 
well-oxygenated cells remains to be investigated in in vitro and in vivo studies. 
 
My thesis studies have demonstrated that exogenous pyruvate plays a critical role 
in cell survival and proliferation in hypoxic tumor microenvironment. Therefore, 
targeting the utilization of exogenous pyruvate may be a potential novel strategy to 
specifically kill hypoxic cancer cells, which are commonly resistant to chemoradiation. 
Since Warburg effect is a common feature of cancer cell metabolism, targeting lactate 
dehydrogenase (LDH) and monocarboxylate transporters (MCTs) has been explored as a 
cancer therapy based on inhibiting the production and export of lactate (Le et al., 2010; 
Polanski et al., 2014). My pyruvate cycle model, in which well oxygenated cells releases 
pyruvate, and hypoxic cell uptake the exogenous pyruvate as oxygen surrogate in 
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metabolism provide more precise targets (Yin et al., 2016). Whereas my studies are 
generally based on specific cell lines, it is expected that the general principle may be 
applicable to other solid tumors as well.  
 
Technically, it is known that cell surface monocarboxylate transporters (MCT1, 2, 
and 4) are upregulated by hypoxia (de Heredia et al., 2010), which may facilitate hypoxic 
cells to uptake exogenous pyruvate. In fact, recent studies have showed the efficacy of 
MCT1/2 inhibitors in killing cancer cells (Le Floch et al., 2011; Polanski et al., 2014). 
Since the release and uptake of pyruvate also are carried out by MCTs, it may be possible 
to block cancer cell utilization of exogenous pyruvate by specifically targeting MCTs 
(Halestrap and Price, 1999). However, although the four major members of MCT family 
(MCT1-4) share substrates including lactate, pyruvate and the ketone bodies, each 
member has distinct tissue distribution, substrate preference and specificity (Table 6-1). 
Considering its ubiquitous expression pattern and a Km within the physiological range of 
pyruvate (50 -100 μM), MCT2 may be the most relevant transporter for cells to release 
and uptake pyruvate (Lin et al., 1998).  Therefore, the role of MCT2 in tumor cell 
adaptation to hypoxia should be further studied. 
 
Recently the mitochondria pyruvate carriers (MPCs) have been identified (Herzig 
et al., 2012). It is reported that inhibition of MPCs promotes tumor growth (Schell et al., 
2014), which also supports the notion that cytosolic utilization of pyruvate as oxygen 
surrogate to recycle NAD+ is the key mechanism for cancer cell to achieve metabolic 
adaptation. Therefore, it is interesting to investigate the role of MPCs in cellular 
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adaptation to hypoxia. 
 
4). Conclusion 
In conclusion, my thesis study illustrates a protective role of exogenous pyruvate 
in cancer and non-cancer cells under hypoxic conditions. The protective effect is 
dependent on the ability of pyruvate to act as an oxygen surrogate to accept electrons, 
hence maintaining the intracellular NAD+ levels to ensure ATP production. The 
biosynthetic role of exogenous pyruvate is generally dispensable. The exogenous 
pyruvate facilitated-continuous ATP production provides an energetic foundation to 
support other adaptive cellular processes such as ER stress response and autophagy, 
which collectively inhibit apoptosis. These findings expand our understanding of 
metabolic adaptation to hypoxia and the important role of exogenous pyruvate in hypoxic 
cells, and may pave a way towards new therapies for hypoxic cancers by targeting 
utilization of exogeous pyruvate.  
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Figure 6-1. Proposed model of exogenous pyruvate-mediated protection of hypoxic 
cells. 
Under chronic hypoxic condition, ATP is decreased to an extremely low level, which 
inhibits ER stress response. Apoptosis overwhelms the cell-adaptive autophagy and 
causes cell death. Exogenous pyruvate acts against chronic hypoxia and maintains ATP 
production, thus guaranteeing activation of ER stress response and inhibiting apoptosis 
through GRP78 upregulation. 
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Figure 6-2. Proposed in vivo pyruvate-lactate cycle in adaption of hypoxia. 
Tissue oxygen concentration decreases as the distance between cells and blood vessels 
increases. Cells in well-oxygenated areas mainly use ETC to regenerate NAD+; and a 
portion of pyruvate generated from glycolysis is released to the circulation, which may 
diffuse to hypoxic region. Hypoxic cells uptake exogenous pyruvate and use it as oxygen 
surrogate to maintain NAD+ availability, avoiding NAD+ depletion and eventual 
inhibition of glycolysis. In turn, the lactate released from hypoxic cells may be up-taken 
by the well-oxygenated cells and be oxidized to pyruvate. 
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Table 6-1. Distribution and pyruvate specificity of MCTs 
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Appendices 
 
       1. Abbreviations 
αKG  alpha-ketoglutarate 
eIF2α  eukaryotic translation initiation factor 2 alpha 
mTOR  mechanistic target of rapramycin 
qRT-PCR  quantitative real-time polymerase chain reaction 
AcAc  acetoacetate  
ACC  acetyl-CoA carboxylase 
AMPK  adenosine monophosphate-activated protein kinase 
ARNT  aryl hydrocarbon receptor nuclear translocator 
ATF4  activating transcription factor 4 
ATF6  activating transcription factor 6 
CA9  carbonic anhydrase 9 
CS   citrate synthase 
CRISPR  clustered regularly interspaced short palindromic repeats 
ECAR  extracellular acidification rate 
ETC  electron transfer chain  
ERK1/2  extracellular signal-regulated kinase 1 and 2 
FCCP  carbonyl cyanide-p-(trifluoromethoxy)phenylhydrazone  
G3P  glyceraldehyde-3-phosphate 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GOT  Glutamic-oxaloacetic transaminase 
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GRP78  glucose regulated protein 78 
HIF  hypoxia inducible factor 
IRE1α  inositol-requiring protein 1 alpha 
LC3B  Light Chain 3B 
LDH  lactate dehydrogenase 
NAD  nicotinamide adenine dinucleotide 
OAA  Oxaloacetate 
OCR  oxygen consumption rate 
PARP  poly(ADP-ribose) polymerases  
PC   pyruvate carboxylase 
PDC  pyruvate dehydrogenase complex 
PDHA1  pyruvate dehydrogenase (lipoamide) alpha 1  
PERK  protein kinase R (PKR)-like endoplasmic reticulum kinase 
PI3K  phosphoinositide 3-kinase 
ROS  reactive oxygen species. 
SREBP  sterol regulatory element-binding protein 
ULK1  unc-51-like kinase 1 
XBP1  X-box binding protein 1 
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